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Abstract 
Injury to the central nervous system (CNS) leaves patients with irreversible loss of critical functions 
such as vision and movement due to the limited regenerative capabilities of CNS axons. Stem cells 
offer two potential means of treating CNS injury, either differentiating into, and replacing lost 
neurons, or indirectly promoting the regeneration of endogenous injured neurons. 
The aim of the present study was to determine the potential benefit dental pulp stem cells (DPSCs) 
could provide in CNS injury. Rat DPSCs were subjected to a three week differentiation medium to 
induce neuronal differentiation. DPSCs were also tested for their potential pro-regenerative 
capabilities in an in vitro (primary retinal ganglion cell (RGC) culture) and in vivo (optic nerve crush) 
CNS injury model. 
DPSCs failed to differentiate into neurons following the three week inductive medium protocol. 
DPSCs, when cultured with primary RGCs, significantly increased the number of regenerating RGC 
neurites. When transplanted into the vitreous, DPSCs significantly increased both survival of RGCs 
and regeneration of RGC axons following optic nerve crush. 
This study although unable to successfully differentiate rat DPSCs into neurons, reveals the potential 
of DPSCs as a candidate cellular therapy in treating CNS injury.
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1 Introduction 
1.1 CNS injury – the clinical problem 
Injury to central nervous system (CNS) tissue is severely debilitating to the patient not only due to its 
critical role in sensory and motor function but also due to the post-mitotic state and regenerative 
capabilities of the tissue. The most common cause of CNS injury is through trauma with 130,000 
people a year (reviewed in Thomas and Moon, 2011) suffering a spinal cord injury (SCI) and 80,000 a 
year (Ghajar, 2000) suffering traumatic brain injury which leads to severe, permanent neurological 
disability. Non-traumatic diseases can also affect the CNS such as glaucoma, a degenerative disease 
affecting the optic nerve which is the 2nd leading cause of blindness (Stone et al., 1997). Since the 
CNS is so functionally important, injury often leaves patients dependant on life-long care and unable 
to work or perform simple tasks and procedures. Thus, CNS injury can be seen as both debilitating to 
the patient and the economy and because of this, remains a huge research interest. 
1.2 Regenerative capability of the CNS 
Neurons, the cells residing in the nervous system which are responsible for the propagation of 
signals through the body, are post-mitotic. For this reason, neurons lost upon injury cannot be 
replaced. As well as the loss of irreplaceable neurons, CNS injuries also crush or sever axons (Figure 
1), which in contrast to the peripheral nervous system (PNS), are incapable of regeneration. The lack 
of regenerative capacity of injured CNS axons can be attributed to both environmental changes 
associated with the injury response and intrinsic factors associated with CNS neurons. 
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Figure 1: The neuronal response to axotomy is depicted. When the axon is severed, the distal segment begins degrading 
via a process known as wallerian degeneration; the remnants of this distal segment remain and stagnate in the 
environment. The proximal end reseals to prevent cytoplasm loss and in the case of the peripheral nervous system, which 
has a high regenerative potential, forms a growth cone. In the central nervous system however, proximal ends are only 
capable of limited abortive sprouting before the growth cone collapses. Cell bodies of the neurons also undergo 
chromatolysis, and without neurotrophic support and reconnection, die by apoptosis (Liu et al., 2011). 
 
1.2.1 Regenerative capability of the CNS – extrinsic factors 
The environmental importance was first revealed over 30 years ago by Richardson and Aguayo when 
they showed that an injured CNS axon could regenerate through a peripheral nerve implant 
(Richardson et al., 1980). This indicated for the first time that CNS axons are not incapable of 
regeneration and the non-permissive environment, the nerve which encapsulates the axons, is the 
limiting factor in their regenerative potential.  This non-permissive environment has two important 
factors; a paucity of growth factors and an abundance of growth inhibitory molecules. 
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Figure 2: On the left, the typical signalling pathways that neurotrophic factors utilize to elicit their growth and survival 
promoting properties. On the right, growth inhibitory molecules signal through small GTPases to induce collapse of the 
growth cone and halt axon regeneration (Berry et al., 2008). 
These growth factors, known as neurotrophic factors (NTFs) have a dual function; not only do they 
promote regeneration of axons but also act as potent survival factors for neurons (Figure 2). 
Neurotrophins, a type of NTF, consist of nerve growth factor (NGF), brain-derived growth factor 
(BDNF) and neurotrophic-3 (NT-3) which bind to the receptors tropomyosin receptor kinase-1, 2 and 
3 (Trk) respectively (reviewed in Berry et al., 2008). They originate from the target organ, aiding in 
the generation of axons during development (Ernfors et al., 1994; Huang and Reichardt, 2001).  
As well as a lack of growth factors, the presence of inhibitory ligands is also a considerable hurdle for 
axon regeneration (Figure 2). Schwab and Caroni showed in 1988 that CNS but not PNS myelin 
induced growth cone collapse of regenerating neurons in vitro and that antibodies raised against 
these proteins could prevent this (Caroni and Schwab, 1988; Schwab and Caroni, 1988). These 
proteins were later termed Nogo for their profound effect at inhibiting axon regeneration. Many 
other myelin-derived inhibitory ligands (MIL) have been revealed since and include myelin-
associated glycoprotein (MAG) and oligodendrocyte-myelin glycoprotein (OMgp) (Benowitz and Yin, 
2007); these can be found stagnating in the environment the distal axon occupied prior to injury 
(Figure 1). Myelin isn’t the only source of inhibitory ligands however, these molecules, termed non-
MIL, also play a significant part in preventing axon regeneration. The gliotic scar, which forms in the 
Neurotrophic factors Inhibitory ligands 
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injury site, is one source of these non-MIL which include ephrins, semaphorins (Berry et al., 2008), 
heparin-, dermatin-, keratin- and chondroitin sulphate proteoglycans (CSPGs) (Benowitz and Yin, 
2007) which all inhibit axon regeneration. 
1.2.2 Regenerative capability of the CNS – intrinsic factors 
Although the extrinsic factors have received the widest attention, intrinsic factors are arguably of 
equal importance. The first intrinsic difference between neurons can be seen when comparing the 
neonatal spinal cord to the fully formed spinal cord. Injury to the spinal cord of a developing rat is 
met with robust and complete regeneration whereas after birth, post-injury regeneration fails (Liu et 
al., 2011). This is seen in other areas of the CNS, such as with the optic nerve with embryonic retinal 
ganglion cells (RGCs) extending axons at 10 times the speed of their mature counterparts. Thus, 
despite no drastic differences in the environment, intrinsic changes to neurons post-birth prevent 
regeneration following CNS injury. 
One of the more well known intrinsic factors is growth associated protein-43 (GAP-43) which is 
expressed by neurons capable of robust regeneration and has been shown to have a causal role 
(Benowitz and Yin, 2007). RGCs when stimulated therapeutically to regenerate also show an almost 
ten times increase in GAP-43 expression (Benowitz and Yin, 2007), an association widely used when 
staining for regenerating axons. Another important intrinsic regulator of axon growth is the 
mammalian target of rapamycin (mTOR) pathway which is both down regulated following birth and 
further down regulated following axonal injury. Forced upregulation of this pathway by deletion of 
its negative regulator phosphatase and tensin homolog (PTEN) promotes robust axon regeneration 
(Park et al., 2008). 
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1.3 Stem cells as a potential treatment 
As outlined above, CNS injury yields two avenues of potential treatment. The first is to promote 
endogenous repair mechanisms and limiting further cell death. This indirect approach owes its 
functional recovery to long distance axon regeneration, reconnecting the soma or cell body of the 
neuron to its original target. The second potential treatment can be seen as a more direct approach, 
replacing post-mitotic neurons lost during the injury. Stem cells, which can be extracted from an 
ever increasing list of sources (Figure 3), can be used in both of these approaches. 
 
Figure 3: Potential sources of stem cells for transplanting into the injured spinal cord are shown. Stem cells can be isolated 
from a variety of different tissues and either transplanted directly into the lesion or differentiated in inductive medium 
prior to transplantation. Some sources such as olfactory system, blood, bone marrow and umbilical cord offer the potential 
for autologous transplantation (Thomas and Moon, 2011). 
1.3.1 Stem cells as a potential treatment – direct support 
The direct approach is what is most widely associated with stem cells in terms of treatment for CNS 
injury. Stem cells are unique in being the only source of primary neurons available for potential 
transplantation. Following transplantation, it is hoped that these neurons will form relays or 
“bridges” that injured axons undergoing endogenous local regeneration can branch onto, essentially, 
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reconnecting the circuit broken previously by the injury. Evidence for this occurring is strong; 
Bareyre et al showed in 2004 that in an untreated injury model of SCI, axons of the corticospinal 
tract (critical for movement) regenerated spontaneously formed new connections with undamaged 
propriospinal neurons (involved in sensing the surroundings) (Bareyre et al., 2004). These new 
connections acted as novel circuits, bridging around the lesion and contributing to functional 
improvement. This experiment shows the potential of both anatomical plasticity (sprouting of axons) 
and functional plasticity (upregulation or alteration of the function of neurons to improve function) 
with many studies reporting similar findings (Blesch and Tuszynski, 2009; Cafferty et al., 2008). This 
process occurring in humans is evident by the fact the 60-80% of individuals who have suffered a SCI 
regain some sensory or motor function, often over many years (Fouad et al., 2011). 
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(Moon and Bunge, 2005). Blocking inhibitory signals within the injured CNS environment also has 
been shown by countless experiments that alone, only promote minor axon regeneration (Benowitz 
and Yin, 2007). Perhaps the best axon regeneration seen to date is a combination of both extrinsic 
agents and forced intrinsic changes to the neurons (Kurimoto et al., 2010), exemplifying the need for 
a combinatorial therapy (multiple agents targeting different signalling pathways combined into one 
treatment). 
Stem cells can act as local factories for a huge array of molecules which can alter the levels of both 
NTFS and MIL/non-MIL, producing a more permissive environment to axon regeneration. The 
advantage over conventional administration of axiogenic agents is that you get continuous 
production which has more of a chance of altering the environment then a single injection. Secondly, 
they can produce a wide array of different factors which is important in tackling the multifocal 
nature of the injury. 
One study showed the potential of this by transplanting bone marrow-derived mesenchymal stem 
cells (MSCs) into a SCI site. They showed that although these MSCs didn’t differentiate, they 
promote both axon regeneration and a reduction in lesion size (Gu et al., 2010). The authors 
attributed this to the fact that these MSCs expressed both BDNF and glial cell line-derived 
neurotrophic factor (GDNF). 
1.4 Dental pulp stem cells 
In 1999 it was shown by Harada et al that cells within the dental pulp are positive for BrdU, a marker 
of dividing cells (Harada et al., 1999). Dental pulp stem cells (DPSCs) were first isolated by Gronthos 
a year later in 2000 (Gronthos et al., 2000) using a plastic adherent assay and were shown to possess 
both self-renewal and multi-lineage differentiation capabilities, two defining features of stem cells. 
Three years later the same group published a paper reporting successful isolation of a stem cell 
population from human exfoliated deciduous teeth, referred to as SHED (Miura et al., 2003). These 
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cells had the same multi-lineage differentiation potential as DPSCs but proliferated faster suggesting 
they are similar to DPSCs but perhaps more immature. 
DPSCs have been shown by multiple studies to express the mesenchymal marker STRO-1 (Gronthos 
et al., 2000) but not the hematopoietic marker CD45 (Miura et al., 2003; Sakai et al., 2012) and 
similar finding are seen in DPSCs from mice (Guimaraes et al., 2011). Other markers both SHED and 
DPSCs appear positive for include CD90, Nestin, GFAP and βIII-tubulin (Sakai et al., 2012). This 
however is controversial since the Gronthos group reports DPSCs are only positive for βIII-tubulin 
post-differentiation, not before (Arthur et al., 2008). Since many other markers appear to be 
differentially expressed depending on the lab doing the analysis, it can be considered that these cells 
have not be fully characterised as of yet. 
1.5 The advantages of dental pulp stem cells 
DPSCs have three advantages over other more widely researched stem cell sources. The first is that 
they are possibly more prone to forming neurons than other stem cells. This is because the majority 
of the tooth, including the dental pulp is derived from the neural crest (Chai et al., 2000) (Figure 6), 
the same neural crest (Figure 5) that forms neurons during development (Huang and Saint-Jeannet, 
2004). Other stem cells on the other hand, do not form neurons, for example NSCs, which despite 
the name, rarely differentiate into neurons and instead form glial cells (Coutts and Keirstead, 2008). 
 
Figure 5: Neurulation is the folding of the neural plate to form the neural tube with the neural crest occupying the dorsal 
region of this tube. These neural crest cells migrate out to form other tissue such as peripheral neurons whereas the rest of 
the neural tube goes on to form the brain and spinal cord (Huang and Saint-Jeannet, 2004). 
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Figure 6: Transgenic mice expressing β-galactosidase in neural crest cells were used, allowing the fate of these cells to be 
mapped throughout development. On the left, a developing mouse tooth at embryonic day 15. The arrows, pointing to the 
inner and outer enamel epithelium, are comprised of β-gal negative cells, given by their pink appearance and thus, are not 
derived from cranial neural crest. The dental papilla (*) on the other hand is dark blue meaning β-gal positive and thus, 
derived from the neural crest. The dental papilla goes on to form both dentin and pulp in later stages of development. On 
the right, an adult mice tooth is shown, derived from the same transgenic mice. The pulp and dentin are both β-gal positive 
(*), thus being derived from neural crest. Scale bars for B and F represent 100µm and 500µm respectively (Chai et al., 
2000). 
The second advantage is that there are fewer ethical consideration than those which shroud other 
stem cells. Most notable is embryonic stem cells which, due to their blastocystic origin, can and is 
argued their use is ethically unjustified. This leads to a lack of support for this research and also a 
reduced number of patients willing to take any potential treatments discovered in the future . 
Thirdly, they are more easily isolated than other stem cells such as MSCs from the bone marrow and 
NSCs from cadavers (Coutts and Keirstead, 2008). Since they are isolated from third molars or 
“wisdom teeth” (Arthur et al., 2008; Gronthos et al., 2000), widely considered vestigial organs, their 
extraction is no loss to the individual and can be expanded with ease or stored without detriment 
(Papaccio et al., 2006). This feature of DPSCs opens up the potential for autologous transplantation, 
removing the need for immunosuppressive therapy. 
1.6 Model of CNS injury 
To understand CNS injury, appropriate models are required, both in vitro and in vivo, which 
recapitulate the pathology that is seen in humans. Each model has its advantages and disadvantages 
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and varies from simple to complex. Most hypotheses driven research begins with the simple models 
and if promising, move forward to be put through more complex and rigorous injury models. 
The most simple of these models is the in vitro RGC culture experiment (Logan et al., 2006). This 
experiment involves the extraction and culture of primary RGCs from an animal (usually a rat) and 
the quantification of both RGC survival and neurite growth under different treatment groups. Since 
the optic nerve which harbours the axons of the RGCs is severed in this model, it replicates the injury 
response seen after CNS injury. 
Moving in vivo, the next simplest model is the optic nerve injury model. The optic nerve is a 
collection of CNS axons, all originating from the RGCs within the retina. For these reason it serves as 
an excellent model of CNS injury since all connections between RGCs and their targets can be 
severed at the lesion site and without disruption of the blood supply (Berry et al., 2008). 
Furthermore, a variety of experimental tools are available such as lens injury (to assess the effects of 
inflammation of axon regeneration) and fluorogold back labelling of RGCs (to accurately quantify cell 
death). Finally, because the cell bodies of the RGCs are directly adjacent to the vitreous, intravitreal 
injections are an easy and non-invasive way of delivering and assessing the efficacy of treatments to 
promote regeneration and RGC survival (Johnson et al., 2010; Logan et al., 2006). 
The most complex of the in vivo models is the animal model of SCI. This model involves contusion or 
transection (complete or partial) of the spinal cord and can be localised to thoracic regions for 
disruption of hind limb function or the more severe cervical region for disruption of forelimb and 
respiration (Moon and Bunge, 2005).The advantages of this model is it more accurately replicates a 
SCI seen in humans. Unlike the optic nerve injury where RGCs are almost completely lost 3 weeks 
post lesion (Berry et al., 2008), neurons within the spinal cord remain relatively quiescent following 
injury, allowing investigators the ability to test the efficacy of drugs in the chronic phase rather than 
just in the acute phase (Moon and Bunge, 2005). Another advantage of this model is it allows 
locomotory function to be assessed using the gold standard BBB locomotor test (Basso et al., 1995). 
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This test has been shown to be reliable and accurate and allows comparisons with other treatments 
tested in other labs to compare efficacy. A drawback of this model is that because the spinal cord is 
a much more complex structure, “sparing” of axons can occur following injury giving the illusion of 
functional recovery following pro-regenerative treatment when infact, recovery is due to these 
spared axons. Another issue is that treatments may promote plasticity such as the sprouting of 
injured neurons onto other non-injured neurons or the potentiation of central pattern generators 
below the lesion site. These scenarios will lead to functional recovery and thus a higher BBB score 
without any long-distance axon regeneration taking place. A final disadvantage is the large reduction 
in animal well being and need for rigorous supervision and care. 
1.7 Current research into DPSCs as a treatment for CNS injury – direct support 
Human DPSCs have been shown by two groups to differentiate into neurons (Arthur et al., 2008; 
Kiraly et al., 2009). The first group, led by Stan Gronthos, used a three week inductive medium 
protocol to differentiate DPSCs into neurons which expressed neuronal markers, took on a neuronal 
morphology and expressed voltage-gated sodium channels (Arthur et al., 2008). The second paper 
published by Kiraly et al used a similar method to induce neuronal differentiation achieving similar 
results but these DPSC-derived neurons also expressed voltage-gated potassium channels (Kiraly et 
al., 2009). Currently only one study has taken this in vivo by transplanting DPSC-derived neurons into 
the cerebrospinal fluid (Kiraly et al., 2011). This study, published by the Kiraly group was a proof of 
principle rather than a measurement of efficacy and showed transplanted cells integrated into host 
brain and survived the duration of the study (four weeks). Interestingly, they also showed that 
transplanted cells preferentially integrated into injured regions of the cortex. Currently no protocol 
exists on the differentiation of rat DPSCs into neurons. 
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the injured spinal cord, preserving myelination. A similar study showed significant recovery of 
sensorimotor function following middle cerebral artery occlusion induced stroke when DPSCs were 
transplanted into the lesion site. The transplanted DPSCs differentiated into an astrocytes-like 
phenotype, rather than neurons, suggesting DPSCs contributed as a support cell via trophic factors 
(Leong et al., 2012). 
1.9 Aims 
The aim of this study is to explore the potential benefits of DPSCs in treating CNS injury, both directly 
and indirectly. To address the issue of a direct benefit, a protocol will be developed to reliably 
differentiate rat DPSCs into neurons based on information from the two papers that have reported 
this using human DPSCs (Arthur et al., 2008; Kiraly et al., 2009). Immunohistochemical and 
morphological differences will be used to assess DPSCs pre- and post-differentiation to determine if 
successful differentiation has occurred. Changes during successive passages will also be analysed. 
To assess any potential indirect benefit, DPSCs will be co-cultured with RGCs and the pro-
regenerative effects can be analysed via measurements of RGC neurite growth. If successful, DPSCs 
will be transplanted into the vitreous of a rat following optic nerve crush (ONC) with subsequent RGC 
survival and optic nerve regeneration measurements done to prove similar effects in vivo. 
1.10 Hypothesis 
Similar to human DPSCs, rat DPSCs can be successfully differentiated into neurons, providing the 
foundation for future in vivo work focused on transplanting DPSC-derived neurons into a SCI site. 
Due to their production of NTFs and “blinding” of neurons to their disinhibitory environment, DPSCs 
will promote significant neurite outgrowth of RGCs in vitro and promote both regeneration of axons 
and survival of RGCs in vivo following ONC. 
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incisors. Incisors were transferred in α-MEM (Biosera, Ringmer, UK) supplemented with 1% 
penicillin/streptomycin (P/S)  to the sterile conditions of a laminar flow hood. The posterior ends of 
the incisors were cracked open and then dental pulp removed. Dental pulp was sliced into pieces no 
bigger than 1mm3 using a scalpel blade and incubated in 4ml of 0.25% trypsin-EDTA for 30 minutes 
at 37°C.  Trypsin was inactivated by adding an equal volume of α-MEM containing 1% P/S and 20% 
foetal bovine serum (FBS; Biosera). A single cell population was obtained by passing through a 70µm 
cell strainer (BD Biosciences, Oxford, UK). The cell suspension was centrifuged at 500 xg for 5 
minutes. Pellets were resuspended in 1ml of α-MEM containing 1% P/S and 20% FBS and seeded 
onto a T25 flask (Corning, Amsterdam, NL) at a total volume of 5ml. Medium was changed every 3 
days and cells were passaged when 70% confluent and cultured at 37°C, 5% CO2. 
2.3.2 Fibroblast cell culture 
Mouse fibroblast 3T3 cells were provided frozen in liquid nitrogen at passage 22 by Gay Smith. Cells 
were defrosted on a 40°C hot plate for 2 minutes before being seeded on a T75 flask (Corning) in α-
MEM containing 1% P/S and 10% FBS. Medium was changed every 3 days and cells were passaged 
when 90% confluent. 
2.3.3 Retinal ganglion cell/dental pulp stem cell co-culture 
Cell culture 8-well chamber slides (BD Biosciences) were prepared by incubating for 90 minutes with 
poly-D-lysine (100µg/ml) and then 30 minutes with laminin (20µg/ml). Cell suspensions of either 
DPSCs (at passage 2) or fibroblasts, both obtained via the protocol above were pelleted, 
resuspended and plated in each well at a seeding density of 20,000cells/well and incubated for 24 
hours at 37°C in 300µl of supplemented neurobasal-A (24.2ml neurobasal-A (Life Technologies, 
Gibco, UK) supplemented with 500µl of B27 supplement (Life Technologies, Invitrogen, UK), 62.5µl 
of L-glutamine (200mM; Invitrogen) and 125µl of gentamycin (Invitrogen)).  
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The following day eyes were obtained from male Sprague-Dawley rats weighing 250g (Charles River) 
and the retinae dissected out. Retinae were minced in 1.25mls of papain (Worthington Biochem, NJ, 
USA) containing 62.5µl of DNase I (Worthington Biochem) and incubated for 90 minutes at 37°C. 
Following this incubation the tissue suspension was centrifuged at 300 xg for 5 minutes and the 
pellet was resuspended in a solution containing 1.35ml of EBSS (Worthington Biochem), 150µl of 
reconstituted albumin ovomucoid inhibitor (Worthington Biochem) and 75µl of DNase I. This cell 
suspension was then added on the top of 2.5ml of albumin ovomucoid inhibitor to form a 
discontinuous density gradient and this was centrifuged at 70 xg for 6 minutes. The resulting pellet 
was resuspended in 1ml of supplemented neurobasal-A and seeded on top of the DPSCs/fibroblasts 
at a seeding density of 125,000. CNTF (200ng/ml) or the Trk receptor inhibitor K252a (50nM) was 
used in some cultures to assess the importance of NTFs in the co-culture. The co-culture was 
incubated for 4 days at 37°C before staining via immunocytochemistry. 
2.3.4 Neuronal differentiation of DPSCs 
Differentiation of DPSCs towards a neuronal lineage was done based on the method given in the 
2008 paper by Arthur et al (Arthur et al., 2008). Cell culture 8-well chamber slides were prepared by 
incubating for 90 minutes with poly-L-ornithine (10µg/ml) and then 30 minutes with laminin 
(20µg/ml). DPSCs at passage 2 were seeded into the chamber wells at a density of 5000, 10000 and 
20000 and allowed to expand in α-MEM containing 1% P/S and 10% FBS for 3 days. After 3 days 
DPSCs were cultured in supplemented neurobasal-A containing 20ng/ml EGF (Peprotech EC, London, 
UK) and 40ng/ml bFGF (Peprotech) for 1 week. After 1 week the medium was changed to DMEM:F12 
containing 1X insulin-transferrin-sodium selenite solution (ITSS; Roche, Burgess Hill, UK), 40ng/ml 
bFGF and 1% P/S. For the 3rd week DPSCs were cultured in DMEM:F12 containing 1X ITSS, 40ng/ml 
bFGF, 1µm retinoic acid, 0.5mM dcAMP and 1% P/S. Controls were DPSCs left in α-MEM containing 
1% P/S and 10% FBS for 3 weeks. 
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2.4 In vivo experiments 
All surgical procedures were carried out under Home Office guidelines in accordance with animal act 
1986 (UK) and after local ethical approval (BERSC). Prof Martin Berry performed the ONC and cell 
injections whereas Rhodamine-B-isothiocyanate (RITC) injections and perfusions were performed by 
myself. Anaesthesia was provided by either myself or Lisa Hill.  Animals were kept in a well-
controlled environment (21°, 55% humidity) in a building adjacent to the laboratory. Animals were 
given food/water ad libitum and kept under a 12 hour light and dark cycle while under constant 
supervision from well trained staff.  Four female Sprague Dawley rats weighing 200-250g (Charles 
River) were used for this experiment, treatment groups given in Figure 9. For anaesthetic induction 
5% Isoflurane/1.5L per minute O2 was used with Isoflurane being lowered to 3.5% prior to surgery. 
The pedal reflex was used to assess animal sedation prior to surgery. 
Beginning 3 days prior to the surgery and maintained for the duration of the study, cyclosporin A 
was used as an immunosuppressant to prevent rejection of transplanted cells. Administration was 
via the drinking water at a final concentration of 100µg/ml. This was under the assumption that the 
rats will drink 20mls a day and thus provide them with the effective amount of 10mg/kg/day. Fluid 
intake was monitored throughout the study to confirm this assumption. 
 
 
 
Figure 9:   The three treatment groups are shown 
on the left with each group consisting of an n of 
4. Data derived from intact eyes, analysed in 
exactly the same way, was readily available. The 
middle treatment group consisted of an optic 
nerve crush (ONC) and intravitreal (ivit) injection 
of 400,000 fibroblasts, both on day 0. The bottom 
treatment group consisted of an ONC and an ivit 
injection of 400,000 dental pulp stem cells 
(DPSCs), both on day 0. Animals were sacrificed 
on day 21. 
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2.4.1 Intravitreal injections 
Following anaesthesia, animals had analgesia administered subcutaneously (buprenorphine 
0.1ml/mg) before their heads were shaved and secured in a head-holding frame. Isoflurane 
administration was maintained at 3.5% throughout the surgery. The head was rotated 45° so the eye 
to be injected is in the superior position. Using angled, non-toothed forceps in the left (non-
dominant) hand the eye was gently exhumed from the socket up to the point where the 
circumference of the limbus can be seen. A sterile cotton bud was used to apply pressure to the 
corner of the eye to aid in exhuming it from the socket. Forceps were tightened briefly to keep the 
eye rigid while minimising the time spent with a compromised blood supply. A glass micropipette 
produced from glass capillary rods (Harvard apparatus, Edenbridge, Kent, UK) using a Flaming-Brown 
micropipette puller (Sutter instruments, California, USA) was preloaded with 400,000 cells 
suspended in 10µl of phosphate-buffered saline (PBS), either fibroblasts or DPSCs, to be injected into 
the left and right eye respectively. Injections were done at the angle shown in Figure 10 and to 
relieve ocular pressure, the eye was injected with a needle tip at a point 180° from the original 
injection site. 
 
 
Figure 10: A diagram of the rat eye is shown. The 
vitreous body is found just posterior to the lens and 
lies adjacent to the retina, making it a useful cavity 
for injecting substances to interact with the retinal 
ganglion cell (RGC) bodies. The injection site and 
angle of injection is also shown, portraying the care 
needed to avoid injuring the lens. Since the vitreous 
is a closed cavity, injection of substances will elevate 
the pressure. To avoid pressure induced damaged to 
RGCs, intravitreal injection with a needle tip at a 
point 180° to the original injection site is done. 
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2.4.2 Optic nerve crush 
ONC was performed concurrently with intravitreal injections with maintained anaesthesia as above. 
Using blunted scissors and toothed forceps a midline incision was made along the scalp. Using fine 
forceps the skin was retracted, and loose connective tissue was separated until the temporal and 
supraorbital ridge were visible. Using the top blade of fine scissors the temporalis muscle was cut 
with a vertical incision. The temporal ridge was cut along in a caudally fashion whilst avoiding the 
ophthalmic vein. After identification of the neurovascular bundle, both ends were clamped and cut. 
The harderian gland was separated from its capsule and to prevent it from moving back a sterile 
tissue strip was placed in the way. The retractor bulbi muscle was removed and a 2nd sterile tissue 
was placed on the opposite side of the first to isolate and visualise the optic nerve. The dural sheath 
that surrounds the optic nerve was removed and the nerve itself, crushed using forceps at the point 
2mm from the optic nerve head. Following surgery, animals were sutured and placed in a heated 
recovery cage. Ten days into the study, animals were examined using fundoscopy with the help of 
Maj Richard Blanch. 
2.5 Tissue preparation 
At the end of the study animals were sacrificed by rising concentrations of CO2 and immediately 
after, fixed by intracardiac perfusion with 4% paraformaldehyde (PFA; TAAB, Reading, UK) in PBS 
with concurrent clamping of the descending aorta to limit perfusion to the head region. 
2.5.1 Dissection 
Eyes were dissected out by cutting around the orbit, separating the eye from the oblique/rectus 
muscles and finally, the optic nerve at the posterior side of the eye. To dissect out the optic nerve, 
skin from the head was peeled anteriorly to reveal the skull and subsequently, bone clippers were 

22 | P a g e  
 
 
2.5.4 Immunohistochemistry 
Sections were allowed to equilibrate to room temperature before being hydrated in PBS for 2 X 5 
minutes. After washes, tissue was permeabilized in 0.1% triton x-100 in PBS for 20 minutes at room 
temperature. Tissue was washed for 2 X 5 minutes in PBS and isolated with a hydrophobic PAP pen 
(Immedge pen; Vector Laboratories, Peterborough, UK). The tissue was blocked (75µl; 0.5% bovine 
serum albumin (g/ml), 0.3% Tween-20, 15% normal goat serum (Vector Laboratories) in PBS) in a 
humidified chamber for 30 minutes at room temperature. After the 30 minutes block, tissue was 
incubated with primary antibody diluted in antibody diluting buffer (ADB; 0.5% bovine serum 
albumin, 0.3% Tween-20 in PBS) overnight at 4°C. The following day slides were left to equilibrate 
with room temperature for 20 minutes before being washed in 3 X 5 minutes of PBS. Tissue sections 
were then incubated with secondary antibody diluted in ADB for 1 hour in a hydrated incubation 
chamber at room temperature. After the 1 hour, slides were washed in 3 X 5 minutes of PBS, 
mounted in vectorshield mounting medium containing DAPI (Vector Laboratories) and stored at 4°C 
prior to microscopic analysis. 
2.5.5 Immunocytochemistry 
Cells were fixed in 4% PFA in PBS for 10 minutes and then washed in 3 X 10 minutes of PBS at room 
temperature. Cells were next blocked in blocking solution for 20 minutes at room temperature 
followed by incubating with primary antibody diluted in ADB for 1 hour at room temperature. After 
the 1 hour, cells were washed in 3 X 10 minutes of PBS and incubated with the secondary antibody 
diluted in ADB for 1 hour at room temperature. The cells were then washed in 3 X 10 minutes of PBS 
and mounted in vectorshield mounting medium containing DAPI and stored at 4°C. 
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2.6 Analysis 
2.6.1 Microscopy 
Analysis of the immunohistochemically and immunocytochemically stained sections was done using 
Zeiss Axioplan-2 fluorescent microscope (Carl Zeiss Ltd, Hertfordshire, UK). For 
immunocytochemistry, RGC counts were done in real-time on the microscope incorporating the 
entire slide. Neurite growth measurements were done by taking images at 20X magnification using 
Axiocam HRc camera and Axiovision software (Carl Zeiss Ltd). Each chamber well was separated into 
9 equal regions and an image of each region was taken, focussing on the largest neurite growth of 
each region. Images were then converted to Tiff format ready for analysis. In vitro RGC neurite 
length was measured using Image Pro Analyzer 6.2 (Media Cybernetics inc, Bethesda, MD, USA). 
Data quantification was done blind with the treatment groups unbeknownst to the experimenter at 
the time of quantification. 
For immunohistochemistry, RGC counts were done on 20µm thick sections of the retina. Four 
sections per animal were used and 4 animals per treatment group. Sections were chosen in the same 
plane by ensuring the optic nerve was visible and counts were done in a 250µm region, either side of 
the optic nerve. Counts from intact eyes, quantified using the same method, were already available 
from a previous study. For in vivo quantification of axon regeneration, 20X magnification images 
were taken along the optic nerve and a composite image was created using Photoshop CS3 (Adobe 
Systems inc, San Jose, CA, USA). Using these images, RGC axon regeneration was quantified by 
counting the number of GAP-43 positive axons extending across a line set at 100µm, 200µm, 400µm, 
800µm and 1200µm from the crush site (identified by laminin+ staining). By using the thickness of 
the nerve at each measurement point, the number of axons/mm width was derived. This value was 
then used to derive ∑ad (the total number of axons extending distance d in an optic nerve with 
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radius r) via the formula below (where t is the section thickness (0.015mm)). This was done for 3 
animals for each treatment, 2 sections per animal.   
          
                               
 
 
2.6.2 Statistics 
Kolmogorov-Smirnov test was used to ensure all data was normally distributed prior to parametric 
testing. After verifying suitability of parametric testing, paired and independent T tests were used to 
test for statistical significance in cases with 2 treatment groups. Where multiple treatment groups 
were present, a one-way analysis of variance (ANOVA) with a Tukey post-hoc test was used. Levene’s 
test was used for assessing whether equal variance could be assumed and hence, the correct P value 
chosen. Significant difference was taken at P values of less than 0.05. 
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3 Results 
3.1 Overview 
DPSCs are positive for glial fibriliary acidic protein (GFAP), nerve growth factor receptor (NGFR-P75) 
and nestin. Following the three week differentiation protocol, DPSCs lost their nestin expression and 
ubiquitously, although very weakly, up-regulated βIII-tubulin expression. 
When co-cultured with RGCs, DPSCs promote significant neurite outgrowth compared to fibroblasts 
which acted as controls. Blocking of the NTF receptor using K252a completely reversed this DPSC-
induced growth potentiation. When transplanted into the vitreous, DPSCs promoted a significant 
increase in RGC survival and RGC axon regeneration following ONC.  
3.2 DPSCs have the potential to provide direct support during CNS injury 
The immunocytochemical staining profiles of DPSCs at passage 0, 2 and 4 are given in figure 11. 
DPSCs are positive for GFAP and negative for βIII-tubulin with the exception of a very small amount 
of cells which showed weak positivity for βIII-tubulin (Panel A). These βIII-tubulin positive cells were 
lost rapidly after subsequent passages (Panel D and G). DPSCs are weakly positive for NGFR-P75 and 
negative for myelin basic protein (MBP) and this observation was unaffected by passage number. 
Finally, subpopulations of DPSCs are positive for nestin which became more apparent with 
increasing passage number (Panel I). 
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Figure 11: Immunocytochemically stained cultures of dental pulp stem cells (DPSCs) at passage 0 (A-C), passage 2 (D-F) and 
passage 4 (G-I). All images are representative of the entire culture. DPSCs were stained for βIII-tubulin and glial fibriliary 
acidic protein (GFAP; A, D and G), myelin basic protein (MBP) and nerve growth factor receptor (NGFR-P75; B, E and H), 
and nestin (C, F and I). In all cases, DAPI was used as a counter stain. The insert in panel A shows a βIII-tubulin positive cell 
(GFAP staining removed). Scale bars represent 50µm. 
 
Following differentiation (Figure 12), DPSCs maintained their strong GFAP expression (panel A). 
Expression βIII-tubulin could be seen in the majority of cells (Panel B) however intensity was very 
weak compared to mature neurons (Figure 13, Panel E). DPSCs remained positive for NGFR-P75 
expression and negative for MBP expression (Panel C). Nestin expression was absent following 
differentiation (Panel D). The control experiment for the differentiation is given in figure 11 (Panel G, 
H and I). These DPSCs, at passage 4, spent three weeks in regular growth medium as opposed to 
three weeks in differentiation medium. 
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Figure 13 contains various staining controls. Panel A, B and C are fibroblasts stained with the 
antibodies used in this study and act as a negative control by showing the absence of staining. Panel 
D is another negative control whereby the primary antibodies are omitted, the lack of staining 
ensures the secondary antibodies have no direct specificity for the cells. Finally panels E-H act as 
positive controls, using retinal cultures which contain a collection of both neuronal and glial cells 
that are positive for the antibodies used. 
Figure 12: Immunocytochemically stained cultures of dental pulp stem cells 
(DPSCs) after undergoing the 3 week differentiation protocol. All images are 
representative of both the entire culture and the 2 animals used. DPSCs 
were stained for βIII-tubulin (B) and glial fibriliary acidic protein (GFAP; A), 
myelin basic protein (MBP) and nerve growth factor receptor (NGFR-P75; C), 
and nestin (D). In all cases, DAPI was used as a counter stain. Scale bars 
represent 50µm. 
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3.3 DPSCs can provide indirect support during CNS injury 
DPSCs, when co-cultured with RGCs promoted a significant increase in the percentage of RGCs 
regenerating neurites (49.9%) compared to either RGCs alone (21.6%) or RGCs cultured with 
fibroblasts (24.8%; Figure 15A). The addition of CNTF to the co-culture of DPSCs and RGCs did not 
significantly increase the percentage of regenerating neurites (51.9%) compared to the co-culture of 
only DPSCs and RGCs (49.9%). A similar trend could be seen when analysing the length of neurites 
instead of number, although no significance was reached (Figure 15B). 
K252a, a blocker of the NTF receptors Trk-1, 2 and 3, significantly decreased both the percentage 
(11.3%) and length (16µm) of regenerating neurites seen when added to the DPSC/RGC co-culture 
Figure 13: Immunocytochemically stained cultures of fibroblasts (A-C) dental pulp stem cells (DPSCs; D) or retinal 
ganglion cells (RGCs; E-H). All images are representative of the entire culture. Fibroblasts acted as negative controls 
and were stained for βIII-tubulin and glial fibriliary acidic protein (GFAP; A), myelin basic protein (MBP) and nerve 
growth factor receptor (NGFR-P75; B) and nestin (C). As a further negative control, DPSCs were stained with both 
primary antibodies omitted (D). Retinal cultures were used as primary controls for βIII-tubulin (E), NGFR-P75 (F), GFAP 
(G), and nestin (H). In all cases, DAPI was used as a counter stain. Scale bars represent 50µm. 
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(Figure 15) compared to co-culture of DPSCs and RGCs alone (49.9% and 118.9µm respectively). 
Although cultures of RGCs alone or with fibroblasts showed some decrease in their number/length 
of regenerating neurites following the addition of K252a, this was not significant. Representative 
images of cultures from the different treatment groups that were used in the quantification are 
shown in figure 14.  
 
 
DPSCs isolated from male rats, when injected into the vitreous of female rats, survived for the 
duration of the study (21 days). Transplanted cells were detected in vivo through the use of an 
antibody to the Y chromosome (Figure 16, Panel D and E). DPSC transplantation promoted a 
significant increase in the survival of RGCs (39.9 RGCs per mm of retina) following ONC compared to 
fibroblast treated (26.0 RGCs per mm of retina), as shown in the graph of figure 16. Both treatment 
groups however still suffered significant RGC death compared to uninjured eyes (87.7 RGCs per mm 
Figure 14:  Immunocytochemically stained retinal ganglion cells (RGCs): 
cultured alone (A and G), with fibroblasts (C and F) or with dental pulp stem 
cells (DPSCs; B, D and E). Fibroblasts acted as the negative control for the 
DPSCs whereas ciliary neurotrophic factor (CNTF) was used as a positive 
control (D). K252a, a neurotrophic factor receptor blocker was used in some 
cultures (E-G). All images are representative of both the entire culture and 
the 3 animals used (per treatment group). All cultures were stained for βIII-
tubulin with DAPI used as a counter stain. Scale bars represent 50µm. 
 
30 | P a g e  
 
of retina). Example images from each treatment group are given in panel A and B with the negative 
control in panel C. 
 
Figure 15: Graph A shows what percentage of the total numbers of retinal ganglion cells (RGCs) in each culture condition 
were growing neurites. Graph B shows, of these growing neurites, the average length of the longest. This average length 
was taken by dividing each chamber well into nine and measuring the nine longest neurites, one per division. All treatment 
groups used three animals. Error bars represent one standard error mean. Blue lines represent significant difference at 
P<0.05. Abbreviations: DPSCs, dental pulp stem cells; RGCs, retinal ganglion cells; CNTF, ciliary neurotrophic factor. 
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Regenerating RGC axons, identified in optic nerve sections by GAP-43 staining, extended across the 
lesion site in DPSC transplanted animals (Figure 17). Animals that received DPSCs had more axons 
positive for GAP-43 at regions both proximal (Figure 17, A and B) and distal (Figure 17, C and D) to 
the crush site. Quantification of the number of GAP-43 positive axons at various distances from the 
crush site is given in Figure 18. At all measured distances from the crush site, animals who received 
DPSCs showed a significantly higher number of regenerating axons. 
Figure 16:  Immunohistochemically stained 20µm thick sections of retina are given above (A-E). Injected cells were 
detected using an antibody to the Y chromosome. Dental pulp stem cells (DPSCs; D) and fibroblasts (E) could be 
detected within the vitreous in the experimental and control eyes, respectively (white arrows). To quantify retinal 
ganglion cell (RGC) survival, cells positive for both DAPI and βIII tubulin were counted in a 250µm region of the RGC 
layer of the retina (A and B). A negative control were the primary antibody was omitted is included (C) with the 
choroid, outer nuclear layer (ONL), inner nuclear layer (INL) and ganglion cell layer (GCL) labelled. All images are 
representative of both the 4 sections per animal used, and the 4 animals per treatment group. In all sections, DAPI 
was used as a counter stain. Scale bars represent 50µm. The histogram (F) shows the number of RGCs in the retina of 
animals following optic nerve crush (ONC) and cell transplantation. RGC counts for intact eyes are also given however 
data is from a separate, earlier study. Error bars represent one standard error mean. Red lines represent significant 
difference at P<0.05 whereas blue represents significant difference at P<0.0001. 
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 Figure 17: Immunohistochemically stained sections of optic nerve, 21 days after optic nerve crush. Treatment 
consisted of intra-vitreal transplantation of either dental pulp stem cells (DPSCs; A and C) or fibroblasts (B and 
D). Sections were stained for GAP-43. Images display both the crush site (A and B; crush site signified by a *) and 
2mm distal to the crush site (C and D). All images are representative of the 3 animals used (per treatment 
group), 2 sections per animal. All images are composites of 4-8 images. Scale bars represent 100µm. 
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Figure 18: The number of regenerating axons in the optic nerve, identified through positive staining for GAP-43, is given at 
various distances from the crush site. Blue bars signify animals that received dental pulp stem cells (DPSCs) whereas red 
bars signify animals that received fibroblasts. Error bars represent one standard error mean. Blue lines represent significant 
difference at P<0.05. 
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4 Discussion 
4.1 Overview 
DPSCs failed to differentiate into neurons following administration of an inductive medium. DPSCs 
significantly increased the neurite outgrowth of primary RGCs in an in vitro co-culture assay. When 
transplanted into the vitreous of rats following an ONC, DPSCs promoted significant increase in both 
RGC survival and axon regeneration. 
4.2 Differentiation of dental pulp stem cells into neurons 
Differentiation of DPSCs into neurons was determined by detecting changes in protein expression via 
immunohistochemistry. To detect changes, it was thus first important to characterise the DPSCs in 
their undifferentiated form. Three separate points were chosen (passage 0, 2 and 4) since it is well 
known that MSCs undergo changes following subsequent passages (Nombela-Arrieta et al., 2011) 
and has even been reported that DPSCs take on a more restricted differentiation potential following 
repeated passages (Yu et al., 2010). 
Since DPSCs have not been fully characterized, conflicting data exists on what proteins these cells 
are positive for. Some studies show DPSCs are strongly positive for βIII-tubulin and nestin both 
before and after differentiation (Sakai et al., 2012). The Gronthos group on the other hand found 
DPSCs to be largely negative for βIII tubulin, only increasing following differentiation (Arthur et al., 
2008). The current study appears to agree with this notion; however, we observed a select 
population of DPSCs positive for nestin whereas the Gronthos group found all DPSCs isolated were 
positive for nestin. Since the isolation procedure was largely the same this could be due to a 
difference in species, since rat was used in this study whereas they used human.  
Overall, it is unwise to say differentiation has occurred due to small changes in protein expression, 
especially considering the scientific community are conflicted on what proteins DPSCs express in 
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even their undifferentiated state. We could speculate that the loss of nestin expression is indicative 
of neuronal differentiation however considering survival of cells was poor in the differentiation 
medium, it may equally be selective death of nestin positive cells following administration of the 
inductive medium. Finally, no neurite expression was seen in these cells which are a key 
morphological characteristic of neurons, providing further evidence that neuronal differentiation did 
not occur in this study. 
4.2.1 Future work 
It is imperative to determine that any supposed DPSC-derived neurons are functional i.e. can fire an 
action potential. This, tested via patch clamp, has been done in a couple of studies (Arthur et al., 
2008; Kiraly et al., 2009) and would need to be done as future work in this study for adequate proof 
of neuronal differentiation by determining the presence of functional voltage gated channels. Only 
when this is proven can it be taken in vivo, transplanting DPSC-derived neurons into a SCI animal 
model and measuring functional recovery through the BBB locomotory test (Basso et al., 1995), as 
has been done with MSC-derived neurons (Cho et al., 2009). 
It is arguable that the above is getting ahead of a more important matter which is the 
characterisation of DPSCs. When some studies show DPSCs are positive for βIII-tubulin (Sakai et al., 
2012) and other use βIII-tubulin expression as proof of differentiation (Arthur et al., 2008), it 
becomes apparent that full characterisation of these cells, taking into account different isolation 
methods and different species, is imperative. Only when you know what you are starting with can 
the differentiation potential of these cells begin to be mapped. 
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4.3 The supportive role DPSCs can provide following CNS injury 
As mentioned previously, a study published early this year showed the positive effect stem cells 
isolated from the teeth can have on CNS injury (Sakai et al., 2012). The improvement in locomotory 
function following cell transplantation into a SCI occurred in the absence of neuronal differentiation. 
Various observations such as remyelination and improved axon regeneration were given in the 
study. The present study used RGCs as a model of CNS injury, both in vitro and in vivo, which as 
discussed earlier, is an effective method of quantifying regeneration. 
When co-cultured with DPSCs, RGCs elicited a significant increase in neurite expression. This 
significance was seen in the number of RGCs expressing neurites, but not in the length of neurites. 
Despite the lack of significance in the latter measuring technique, a similar trend was seen to that in 
the former measuring technique. It is likely that the lack of significance is due to the greatly reduced 
sample size used when measuring neurite length, as opposed to counting all RGCs that are growing 
neurites. 
 This regenerative response was attenuated in the presence of K252a, a blocker of the NTF 
receptors. This is in agreement with recent evidence that shows DPSCs expressing a wide array of 
different NTFs (Sakai et al., 2012). Since the augmented regeneration was absent when K252a was 
added, the experiment strongly suggests that DPSCs promoted regeneration of RGC neurites through 
their secretion of these NTFs. Since the addition of CNTF provided no extra benefit, it is likely that 
RGCs had already reached a point of saturation in terms of NTFs via the DPSCs, meaning that the 
limiting factor in regeneration is through other pro-regenerative mechanisms. 
NTFs possess another important characteristic which is the pro-survival effect on neurons. Axotomy 
removes a neurons supply of NTFs and thus the neurons subsequently dies. Quantification of RGC 
survival was not done in the co-culture assay due to the variability in RGCs that would seed down 
around the DPSCs. Variation in DPSC survival, division rate, size and seeding density meant the area 
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of the laminin coated chamber free for RGCs to grow on was varied between experiments. Thus, 
although quantifying regeneration was possible by calculating as a percentage of total RGCs, total 
RGC counts was an unreliable measure of cell survival, likely more reliant on the above factors. 
Although RGC survival was not quantified in vitro, it was done in vivo. Following ONC, RGCs begin 
dying after five days and around 80-90% are dead following three weeks (Berry et al., 2008), thus 
making this a suitable model to assess survival. Our method for quantifying survival relied on 
counting RGCs (βIII-tubulin positive cells in the RGC layer) in a select region however slight variations 
in sectioning and embedding technique and a small sample (in relation to the whole retina) mean 
the method is inferior the gold standard fluorogold technique (Berry et al., 2008). 
RGC survival was quantified and found to be significantly higher than control eyes that received 
fibroblasts instead of DPSC transplantations. This is in agreement with the study that transplanted 
DPSCs into the SCI of rat and showed reduced numbers of cells undergoing apoptosis (Sakai et al., 
2012). Two other studies have shown significant RGC survival follow intravitreal cell transplantation. 
The first using mesenchymal stem cells in an animal model of glaucoma (Johnson et al., 2010), and 
the second using fibroblasts genetically modified to express NTFs in an ONC animal model (Logan et 
al., 2006). Both studies showed significant survival and both attributed this effect to the release of 
NTFs by the transplanted cells. There was however, still substantial RGC death (over 50%) which is 
seen in many studies at these timeframes, even those using caspase inhibitors (Ahmed et al., 2011). 
This aspect of the study would benefit from two improvements, dedicating animals purely for RGC 
survival analysis (i.e. using fluorogold) and secondly, quantifying RGC death at an earlier time point 
as well as three weeks. Another minor criticism is that the RGC count data from intact eyes was from 
an earlier study using male rats whereas the present in vivo study used female rats. With no 
reported difference in RGC numbers between male and female rats however, we did not consider it 
ethically justified to repeat that portion of the experiment. 
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Due to the promising neurite outgrowth results from the in vitro co-culture, it was hypothesised that 
a similar response would be seen in vivo with the ONC model. As expected, when transplanted into 
the vitreous, DPSCs promoted a significant increase in regenerating axons at all distances measured. 
GAP-43 was used to identify regenerating axons which is currently the gold standard for quantifying 
axon regeneration (Berry et al., 2008). The regeneration seen mimics other studies using intravitreal 
cell transplantation to promote axon regeneration (Logan et al., 2006). As well as more pronounced 
regeneration at the proximal stump, the distal region also showed significantly more GAP-43 positive 
axons, an important observation considering full long distance axon regeneration is required to 
restore function. It is these long distance regenerating axons that likely contributed to the 
restoration of function seen in the study transplanting DPSCs into a SCI (Sakai et al., 2012). 
Despite regeneration occurring, the distance and quantity of regenerating axons is not as significant 
as some recent papers that use combinatorial strategies (Kurimoto et al., 2010). Due to this it is 
likely that DPSCs are promoting regeneration through the NTFs they release but by no other means 
and thus not in a combinatorial fashion. A future experiment would be to block the NTF receptors in 
vivo following DPSC transplantation, much like what was done for the in vitro experiment and 
determine if this is the only means by which they promote regeneration. Another possible way 
regeneration occurred is through triggering an inflammatory response since inflammation is a well 
known strong potentiator of axon regeneration (Benowitz and Yin, 2007). This however is unlikely 
since animals were on immunosuppressants and control animals that received fibroblast 
transplantations would also be expected to have an inflammatory response if this was the case. 
Another interesting experiment is to compare DPSC with other tooth-derived stem cells such as 
SHEDs. A future consideration is whether fibroblasts are a suitable control for the DPSCs or whether 
freeze-thawed DPSCs would be better. The primary issue with comparing DPSCs to control dead 
DPSCs is you are comparing dividing cells to non-dividing cells. It is thus desirable to use both 
fibroblasts and dead DPSCs as two separate controls. Rat fibroblasts rather than mouse fibroblasts 
should also be used in future experiments. 
39 | P a g e  
 
Despite their apparent monotherapeutic mode of action however, DPSCs represent a continuous, 
maintained source of NTFs, evident by the fact they are still present within the eye 21 days post-
transplantation. A future analysis would be to determine survival rate of DPSCs following 
transplantation which may reveal if a second “booster” injection is required at some desired time 
point in the study. One future experiment would be to combine DPSC transplantation with another 
long term therapy, but intrinsic rather than extrinsic, such as genetic deletion of pten to determine 
any synergistic effects. A second future experiment would be to see if transplantation of DPSCs into 
the lesion site is more efficacious than intravitreal injection. Although it is considered that axons will 
grow towards the source of NTFs but not away and hence become trapped in the lesion site (Berry 
et al., 2008), this is not always the case. For example one such study that transplanted fibroblasts 
expressing NT-3 into the lesion site promoted axon regeneration without these axons becoming 
trapped in the graft (Grill et al., 1997).  
4.4 Conclusion 
In conclusion the differentiation protocol used failed to induce differentiation of DPSCs into neurons. 
DPSCs however were still shown to possess potential in CNS injury but in their undifferentiated form. 
DPSCs could promote RGC axon regeneration in both in vitro and in vivo models of CNS injury and 
secondly, were neuroprotective in the in vivo model. 
Although regeneration was not as robust as other studies that use a combination of treatment 
strategies, DPSCs are a unique candidate for cellular therapy in CNS injury with the potential to 
become one part of a successful combinatorial therapy. By acting as a continuous source of NTFs 
with the capabilities for autologous transplantation, DPSCs can fill one of many important niches in 
what would be required to create a successful pro-regenerative therapy. 
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Abstract 
Proliferative vitreoretinopathy (PVR), a sight threatening disease, is the major complication in the 
surgical treatment of retinal detachment. It is associated with intraocular fibrosis in the eye, often 
manifesting as membranes layering on top of, or underneath, the retina. These abnormal 
membranes can lead to further retinal detachments via myofibroblast-induced traction, ultimately 
causing blindness. 
The aim of the present study was to develop a rat model of PVR by dual-intravitreal injection of 
transforming growth factor-β2 (TGF-β2) and fibroblast growth factor-2 (FGF-2) - with or without a 
retinal detachment induced by subretinal hyaluronate injection. Decorin, an anti-fibrotic agent, was 
tested for therapeutic efficacy at preventing PVR in the proposed model. 
Immunohistochemistry was inappropriate for quantifying changes in the expression of specific 
fibrotic proteins. Western blots, however, showed an elevation in both laminin and fibronectin levels 
after TGF-β2/FGF-2 injection with levels of laminin reduced following treatment with Decorin. Retinal 
detachment induced elevations in laminin and fibronectin levels and, when combined with 
intravitreal TGF-β2/FGF-2 injection, also induced elevations in α-smooth muscle actin
+ 
myofibroblasts. 
This study demonstrates that retinal detachment combined with intravitreal TGF-β2/FGF-2 injection 
is the best model to induce PVR and that Decorin is a promising anti-fibrotic treatment in this 
context. 
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1.2 Proliferative vitreoretinopathy – an overview 
Proliferative vitreoretinopathy (PVR) is a sight threatening disease affecting the vitreous and retina. 
It is an exaggerated and deleterious ocular wound healing response and, as such, often occurs 
following ocular injuries such as rhegmatogenous retinal detachment (RRD). Although surgery to 
reattach the retina has become progressively more successful, PVR is still the most common 
complication and reason for surgical failure in RRD (reviewed in Pastor, 1998). The defining feature 
of PVR is the formation of fibrocellular membranes (Figure 2; (Charteris, 1995). These membranes 
can be seen subretinally, epiretinally and/or within the vitreous (Hiscott et al., 1999), applying 
traction on the retina which can induce retinal breaks at new or previously treated sites and induce 
tractional retinal detachment and ultimately blindness (Pastor, 1998). 
 
Figure 2: High-resolution spectral optical coherence tomography images in both grey-scale and colour of patients with 
proliferative vitreoretinopathy. Epiretinal membranes can be seen (arrows) that have formed on top of the retina (Brar et 
al., 2009). 
1.3 Aetiology, current treatment and prognosis 
PVR can occur in the context of many different ocular pathologies, such as RRD and trauma also a 
complication of their surgical treatments (Machemer, 1988). The incidence of PVR in patients with 
RRD ranges from 5-11% whereas in patients with more serious conditions such as giant retinal tears, 
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16-41% go on to develop PVR. Penetrating ocular trauma leads to PVR in 10-45% of patients 
(reviewed in Charteris et al., 2002). 
Currently the only treatment for PVR is a surgical approach. Like RRD, detached retina is the primary 
pathology in PVR and so closure of any retinal breaks and retinal reattachment is the goal for the 
surgeon. For mild PVR, external scleral buckling remains a relatively non-invasive and successful 
technique (Charteris, 1995). For more severe cases of PVR, removal of epiretinal and subretinal 
membranes is necessary to treat the tractional forces they apply on the retina. Cryotherapy or laser 
photocoagulation may also be needed to induce adherence of regions of the broken retina to the 
choroid through the scarring response. Finally an intraocular tamponade such as silicone oil or the 
gas fluoropropane is used to help with retinal reattachment (Charteris, 1995). 
Despite the Silicone study reporting an anatomical success rate of 77-79% (Charteris et al., 2002), 
patient’s visual outcome remains poor and, as such, has led many to question whether surgery for 
PVR is justifiable (Mccormack et al., 1994). In the Silicone study, only 25% of post-operative PVR 
patients achieved a vision of 10/100 or greater (Charteris et al., 2002). Despite this over half of post-
operative PVR patients did not regret having the surgery with just under half of patients saying the 
surgery was of some benefit to their vision (Mccormack et al., 1994). 
1.4 Pathogenesis 
PVR is an exaggerated form of wound healing after vitreoretinal injury and experimental evidence 
reveals three phases in its pathogenesis, similar to the three phases of a normal wound healing 
response (Pastor, 1998). This process, based on clinical findings, takes approximately 1-2 months 
(Pastor et al., 2002) and it is likely that the phases overlap significantly. 
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1.4.1 Phase I - Inflammation 
Inflammation is a cascade of events after injury which aims to eliminate any remaining pathogens, 
clear damaged tissue and initiate the endogenous wound healing process (Gilbert et al., 1988). It 
starts with the initial injury itself, due to the breakdown of the blood-ocular barrier and the invasion 
of platelets into the lesion site. These platelets initiate an inflammatory cascade by recruiting 
inflammatory cells such as macrophages into the lesion site, although other sources of macrophages 
such as hyalocytes and retinal microglia have also been suggested to be involved (Gilbert et al., 
1988). This recruitment is regulated by growth factors/cytokines that the platelets secrete, such as 
transforming growth factor-β (TGF-β) and platelet derived growth factor (PDGF), whereas the 
macrophages entering the lesion site begin secreting many other factors including fibroblast growth 
factor (FGF). Studies on human vitreous show significantly increased levels of FGF, PDGF (Cassidy et 
al., 1998) and TGF-β2 (Connor et al., 1989) in eyes with RRD that goes on to develop PVR. 
 Since larger retinal injuries are associated with a higher incidence of PVR (Charteris et al., 2002), it is 
possible that this is due to a more extensive breakdown in the blood-ocular barrier. Many other risk 
factors for PVR, such as vitreous haemorrhage and cryotherapy, are also associated with 
inflammation and breakdown of blood ocular barriers (Charteris, 1995; Mccormack et al., 1994). 
This, however, cannot be the only instigator of PVR since diseases such as uveitis coincide with 
blood-ocular barrier breakdown but are rarely associated with PVR (Pastor et al., 2002). 
 Another important cell playing a role in this condition is the retinal pigment epithelial (RPE) cell 
which rests on a basement membrane known at Bruch’s membrane, found between the retina and 
choroid (Hiscott et al., 1999). Retinal injury, as well as possible imbalances in matrix 
metalloproteinases and their inhibitors (Hiscott et al., 1999), free these cells, which migrate out in 
response to endogenous growth factors in the subretinal space, such as PDGF (Pastor, 1998). These 
RPE cells have been shown to differentiate into macrophages, complementing those in the 
inflammatory response, and also fibrocyte-like cells, complementing the scar formation of the 
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second phase (Machemer, 1988). It is suggested that this response by RPE cells is due, in part, to the 
loss of contact with their neighbouring photoreceptors in the retina (Agrawal et al., 2007). 
1.4.2 Phase II - Proliferation and scar formation 
FGFs, derived mostly from macrophages, stimulates the proliferation of fibroblasts, the cells 
responsible for the production of the extracellular matrix (ECM) and the formation of epiretinal 
membranes (Pastor, 1998). Although the origin of the fibroblasts is not fully known, RPE cells and 
astrocytes are two likely sources (Pastor et al., 2002). RPE cells undergo a special type of 
dedifferentiation known as epithelial-mesenchymal transition (EMT) whereby cells lose their 
epithelial morphology, taking on a more mesenchymal morphology and protein expression pattern 
(Pastor et al., 2002). These resulting myofibroblasts are positive for α-smooth muscle actin (α-SMA) 
and contribute to scar formation and contraction in PVR (Pastor et al., 2002). 
PDGF, as well as potentiating the migration of RPE cells, stimulates their proliferation causing RPE 
cells to become a large component of epiretinal membranes. This stimulation occurs in an autocrine 
fashion as RPE cells themselves have been shown to produce PDGF (Cassidy et al., 1998). The 
interaction of RPE cells with epiretinal membranes is likely to be through their β1 integrin receptors 
which usually anchor the cells to Bruch’s membrane by binding to the laminin and collagen 
membrane components (Hiscott et al., 1999). 
Glial cells, such as astrocytes and Müller cells, undergo astrogliosis in response to many types of 
neuronal injury (Berry et al., 2008; Pastor et al., 2002) which results in an astrogliotic scar. This scar, 
usually dedicated to walling off the injured neuronal tissue (reviewed in Rolls et al., 2009), is 
produced, to some degree, in PVR were it contributes to the pathology. These glial cells are derived 
from the retina and migrate out to proliferate on available membrane surfaces, forming another 
large component of epiretinal membranes (Machemer, 1988). Despite their importance in other 
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parts of the nervous system, their role in repairing the injured retina is not understood (Pastor et al., 
2002). 
Macrophages form another integral part of epiretinal membranes, being identified in 84-100% of 
epiretinal membrane samples from patients, in both acute and chronic (over 4 months old) 
epiretinal membranes (Gilbert et al., 1988). As well as contributing significantly to the cellular 
portion of epiretinal membranes, macrophages are involved in the formation of scar tissue. 
1.4.3 Phase III - Scar modulation and epiretinal membrane contraction 
Fibronectin and fibrin, originating from the serum following injury and ocular-blood barrier 
breakdown, forms a temporary ECM in the early phase of the wound healing response, concurrent 
with the initiation of inflammation. Later in the process, TGF-β orchestrates the deposition of a more 
permanent scar comprised of RPE cell-derived fibronectin, laminin and collagens (Connor et al., 
1989; Hiscott et al., 1999; Pastor et al., 2002). Macrophages are also responsible for fibronectin 
deposition in both acute and chronic epiretinal membranes (Gilbert et al., 1988). Overall, ECM and 
epiretinal membranes have been shown to contain collagen I, III, IV, V, laminin, fibronectin and 
tenascin (Hiscott et al., 1999; Pastor, 1998; Pastor et al., 2002). Collagen II is also found in epiretinal 
membranes, although it is also found in healthy vitreous, thus it is unknown if it is truly upregulated 
or just captured from the surrounding tissue (Hiscott et al., 1999). Myofibroblasts, positive for α-
SMA within the PVR scar tissue, apply tractional force to the retina and are ultimately responsible for 
repeated or new retinal redetachment (Kita et al., 2008; Pastor et al., 2002). 
 As the scar matures and its collagen density increases, the cellular components are removed via 
necrosis and phagocytosis of degenerate cellular material, possibly due to the increasingly fibrotic 
environment being deleterious to the cells (Hiscott et al., 1999). Visual loss is the end result of 
retinal detachment and studies seem to agree that the mechanism is photoreceptor apoptosis (Cook 
et al., 1995). This apoptotic response is possibly due trophic deprivation and separation from the 
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RPE. Other responses by photoreceptors to retinal detachment termed “remodelling” - include the 
redistribution of opsin proteins to the cell body and increased neurite extension (Charteris et al., 
2002). 
1.5 Animal models and experimental treatments 
Although surgery remains the only routine treatment for PVR, various therapeutic agents have been 
designed and tested in clinical trials, which specifically target the cellular and molecular components 
involved in the three phases of scarring detailed above and believed to be critical to the pathology of 
PVR. To test these agents, over 25 animal models have been developed, all which attempt to 
recapitulate the pathogenesis of PVR (Agrawal et al., 2007). 
The injection of cells into the vitreous is one category of PVR models. These models rely on injection 
of cells known to proliferate in the vitreous of PVR patients and contributing to epiretinal 
membranes, including fibroblasts, RPE cells and activated macrophages. Regardless of which cell is 
injected, the resultant epiretinal membranes often comprise multiple different cells that are seen in 
the human condition. Other models inject growth factors/cytokines, or cells that transgenically 
express growth factors known to be important in PVR, such as PDGF. Finally, other models mimic the 
initial insult by, (1) surgically damaging the retina to release RPE cells, (2), injecting hyaluronate 
subretinally to detach the retina or, (3), injecting autologous blood to mimic trauma (Agrawal et al., 
2007). 
Anti-proliferative agents which target the cell proliferation phase during the pathogenesis of PVR 
have been tested in clinical trials. Two of these compounds are 5-fluorouracil and daunomycin 
which, although well tolerated by the eye, produced minimal improvements in surgical success with 
no improved visual outcome (Charteris, 1995; Charteris et al., 2002).  Another anti-proliferative 
agent tested is retinoic acid which inhibits RPE proliferation and differentiation. It appears that, 
following retinal detachment, RPE cells are no longer in the presence of retina-derived retinoic acid 
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so they undergo proliferation and differentiation (Charteris, 1995). A study administering retinoic 
acid intravitreally via a slow release mechanism reported some success in an animal model of PVR 
(Giordano et al., 1993). Corticosteroids have also been implicated as a viable therapy both for their 
anti-inflammatory and anti-proliferative effects (Machemer, 1988). 
The ECM, particularly that which makes up the epiretinal membranes and associated scar is another 
potential drug target.  One drug that has been 
extensively studied is heparin which not only targets 
fibrin, responsible for the initial scar, but also binds and 
sequesters the activity of growth factors such as FGF 
and PDGF and thereby inhibits RPE cell proliferation. 
Although promising, heparin is also associated with an 
increased incidence of intraoperative bleeding 
(Charteris, 1995). 
 
1.6 Fibrosis in proliferative vitreoretinopathy 
Fibrosis is a critical step in the pathobiology of PVR. 
TGF-βs, a family of multifunctional cytokines which exist 
as three isomers in mammals termed TGF-β1, TGF-β2, 
and TGF-β3, are pivotal in this process. Upon secretion, 
TGF-β is activated extracellularly before eliciting its 
cellular effects through a receptor complex and the 
Smad signalling pathway, depicted in Figure 3 (reviewed 
in Blobe et al., 2000). Other signalling pathways 
activated by TGF-β are continuously being uncovered; 
Figure 3: Transforming growth factor-β (TGF-β) 
signals through membrane bounds receptors 
known as RI, RII and RIII. TGF-β binds RIII which is 
presented to RI with the help of RII, leading to the 
phosphorylation of RI. TGF-β can also 
phosphorylate RI directly. Smads, intracellular 
transcription factors which make up the signalling 
pathway for TGF-β subsequently become activated. 
Smad2 or Smad3 become phosphorylated by RI 
which then complex with Smad4. This complex 
travels to the nucleus and through activation of 
gene transcription, induces the effects listed above. 
Two other Smads, Smad6 and Smad7 lack the 
ability to be activated by RI serving instead to only 
interfere with the signalling process. For this 
reason, Smad6 and Smad7 can be seen as inhibitors 
to the Smad signalling cascade (Blobe et al., 2000). 
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one example being the RhoA pathway which is implicated in myofibroblast contraction (Derynck and 
Zhang, 2003; Kita et al., 2008). 
As well as being elevated in the vitreous of patients with PVR (Connor et al., 1989), TGF-β increases 
the contraction of collagen fibres in an in vitro model of PVR (Pena et al., 1994). It is secreted by RPE 
cells, a dominant cell in epiretinal membranes. Injection of TGF-β and fibronectin into the vitreous of 
animals following a retinal injury induces intraocular fibrosis and tractional retinal detachment 
(Connor et al., 1989). 
As mentioned previously, a cellular contributor to PVR fibrosis are myofibroblasts, which are derived 
from RPE cells through a specialised type of differentiation known as EMT. A study using 
experimental detachment of the retina in Smad3 knockout mice showed that the EMT of RPE cells is 
completely blocked, revealing that TGF-β signalling through the Smad pathway is critical for RPE cell  
EMT (Saika et al., 2004). The study then showed that without EMT, deposition of fibrous tissue and 
the formation of a retinal scar fails to occur in this trauma-induced mouse model of PVR. Smad7, an 
inhibitor of the TGF-β signalling pathway (Figure 3), can be overexpressed in cells via transfection 
which results in inhibition of the Smad pathway. When eyes from an animal model of PVR were 
transfected with Smad7, EMT and scar formation was inhibited (Saika et al., 2007).  
As well as causing fibrosis, myofibroblasts contribute to the contraction of retinal membranes and 
the resulting tractional retinal detachment. Although TGF-β is implicated indirectly because it 
promotes EMT, it is also involved directly in epiretinal membrane contraction. This is because TGF-β 
activates other, Smad-independent signalling pathways, one of which is RhoA (Derynck and Zhang, 
2003; Kita et al., 2008). The RhoA pathway is involved in contraction via the phosphorylation of 
myosin light chain (MLC). Contraction of collagen gels in response to vitreous samples from patients 
with PVR is strongly correlated with the concentration of activated TGF-β2 (Kita et al., 2008). This 
MLC phosphorylation and resultant contractile response was inhibited by either antibodies to TGF-β 
or fasudil, a specific inhibitor of the RhoA pathway. Fasudil, when injected into the vitreous of 
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animals with experimental PVR, prevented tractional retinal detachment and thus preserved retinal 
cell viability. 
1.7 Decorin, a potential treatment for PVR 
The large role TGF-β plays in PVR combined with the observation that it is increased in PVR patients 
(Connor et al., 1989) has made TGF-β a potential therapeutic target for future treatments. Although 
antibodies against TGF-β exist, a natural inhibitor was discovered in 1990 (Yamaguchi et al., 1990), 
termed decorin. Decorin belongs to a group of molecules known as small leucine-rich proteoglycans 
and is found “decorating” collagen fibrils, thus contributing to collagen fibrillogenesis. Decorin plays 
a role in wound healing through facilitataly ECM remodelling, with one mechanism being the 
induction of matrix metalloproteinases (Iozzo, 1997). Decorin’s ability to attenuate fibrosis through 
inhibition of TGF-β was shown to be effective at preventing the scarring associated with 
experimental kidney disease (Border et al., 1992) and penetrating brain injury (Logan et al., 1999). 
Other studies have highlighted an anti-fibrotic mechanism of decorin, independent of its ability to 
antagonize TGF-β (Fukui et al., 2001). 
Decorin has been tested as a treatment for a variety of ocular disorders such as conjuctival scarring 
following glaucoma filtration surgery (Grisanti et al., 2005) and corneal scarring which often follows 
refractive laser surgery (Mohan et al., 2010), both studies giving promising results. Finally, Decorin 
has been shown to be effective after experimental retinal injury-induced PVR, significantly reducing 
tractional retinal detachment (Nassar et al., 2011). Unfortunately no detailed histopathological 
analysis was done.  
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1.8 Aims 
The aim of this study was to develop a rat model of PVR using intravitreal injections of FGF-2 and 
TGF-β2 combined with retinal detachment induced by subretinal injection of Healon. Decorin, a TGF-
β antagonist, was assessed as a potential treatment for PVR, both as a preventive therapy, given 
during the development of PVR and as a curative therapy, given following the establishment of PVR. 
1.9 Hypothesis 
Intravitreal TGF-β2 and FGF-2 induces PVR in rats placing their presence in patients with PVR as 
potentially causative. Decorin, a known inhibitor of TGF-β with anti-fibrotic properties prevents PVR 
or, if given after PVR is established, ameliorates the fibrosis associated with the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 | P a g e  
 
2 Material and methods 
2.1 Reagents 
All reagents in this project were provided by Sigma (Poole, UK) unless otherwise stated. TGF-β2 
(Peprotech, London, UK) was supplied and intravitreally injected at a concentration of 5µg/ml. It was 
injected in a volume of 3.5µl which, assuming the vitreous volume of an adult rat is approximately 
50µl (Berkowitz et al., 1998), would produce a working concentration of approximately 350ng/ml. 
FGF-2 (Abcam, Cambridge, UK) was supplied at a concentration of 50µg/ml and diluted to 1µg/ml in 
sterile PBS. It was injected in a volume of 2.5µl to produce a working concentration of 50ng/ml 
which is within its active range (Logan et al., 2006). Decorin (Galacorin™; Catalent Pharma Solutions, 
Middleton, UK) was used at a concentration of 5mg/ml in PBS and injected in a volume of 4µl to 
produce a working concentration of approximately 400µg/ml in the rat vitreous. This is an effective 
concentration since other studies using 2kg rabbits have injected 100-200µg of Decorin which, based 
on the rabbit vitreous volume being approximately 0.5ml/kg body weight (Shafiee et al., 2008), 
would produce a working concentration of 100-200µg/ml. Healon 0.25% was made up from Healon 
2.3% (Abbot Medical Optics, California, USA) diluted in sterile PBS. Antibodies used were from 
Sigma, Abcam (Cambridge, UK), Serotec (Oxford, UK), Molecular Probes (Leiden, Netherlands) and 
GE Healthcare (Buckinghamshire, UK) (Table 2). 
2.2 Experimental design 
The experiment was designed to test the induction and attenuation of PVR in the rat after 28 days 
and utilized 4 animal groups, each group comprised of 4 animals (Table 1). 
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Animal Group 1 (n=4) Animal Group 2 (n=4) 
Left eye Right eye Left eye Right eye 
Retinal detachment 
(Day 0) + ivit injection of 
PBS (Day 0 and 2) 
Retinal detachment (Day 0) 
+ ivit injection of TGF-β2 
and FGF-2 (Day 0 and 2) 
Ivit injection of 
PBS(Day 0 and 2) 
Ivit injection of TGF-β2 and 
FGF-2 (Day 0 and 2) 
Animal Group 3 (n=4) Animal Group 4 (n=4) 
Bi-weekly PBS injection 
(beginning day 14) 
Bi-weekly Decorin 
injections (beginning 
day 14) 
Bi-weekly PBS injection Bi-weekly Decorin 
injections 
Left eye Right eye Left eye Right eye 
Ivit injection of TGF-β2 
and FGF-2 (Day 0 and 2) 
Ivit injection of TGF-β2 
and FGF-2 (Day 0 and 2) 
Ivit injection of TGF-β2 
and FGF-2 (Day 0 and 2) 
Ivit injection of TGF-β2 
and FGF-2 (Day 0 and 2) 
 
 
 
 
 
 
 
 
Table 1: The experimental design is given above including a table of the 4 animal groups with the treatments they received 
and a timeline of the study. All animals received a retinal injury by trans-scleral needle puncture. Animal groups 1 and 2 are 
aimed at creating the rat model of proliferative vitreoretinopathy (PVR). Group 1 received, in the right eye, subretinal 
Healon (day 0) with intravitreal (ivit) injection of transforming growth factor-β2 (TGF-β2) and fibroblast growth factor-2 
(FGF-2) on both day 0 and day 2. The left eye served as the control, with growth factors replaced by phosphate-buffered 
saline (PBS) of an equal volume. Group 2 was the same as group 1 but with subretinal Healon omitted. Group 4 was the 
same as group 2 however they also received bi-weekly injections of Decorin in the right eye to assess its potential as a 
therapy for treating PVR. To control for the Decorin, the left eye received bi-weekly PBS injections instead of Decorin. 
Group 3 was the same as group 4 except bi-weekly injections of Decorin/PBS were delayed by 2 weeks to assess its ability 
to reverse an already established scar. All animals were sacrificed on day 28. Western blots were performed on group 1 
and 4 while immunohistochemistry was done on group 2 and 3. 
2.3 Animals 
Sixteen female Lister-Hooded rats weighing 170-200g were used for this experiment. All surgical 
procedures were carried out under Home Office guidelines in accordance with animal act 1986 (UK) 
and after local ethical approval (BERSC). Animals were kept in a temperature and humidity 
controlled environment (21°, 55% humidity). Animals were given food/water ad libitum and kept 
under a 12 hour light and dark cycle with a daytime luminance of 80lux.  For anaesthetic induction, 
5% Isoflurane/1.5L per minute O2 was used with isoflurane being lowered to 3.5% prior to surgery. 
The pedal reflex was used to assess animal sedation prior to surgery. 
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2.4 Intravitreal injections 
Isoflurane administration was maintained at 3.5% throughout the surgery. The head was rotated 45° 
so the eye to be injected was in the superior position. Using angled non-toothed forceps, the eye 
was gently prolapsed from the socket up to the point where the limbus was seen. A sterile cotton 
bud pressed posterior to the eye aided in prolapsing it. Forceps were tightened gently around the 
eye to keep it rigid without compromising its blood supply. A glass micropipette produced from 
pulled glass capillary rods (Harvard apparatus, Edenbridge, Kent, UK) using a Flaming-Brown 
micropipette puller (Sutter instruments, California, USA) was preloaded with TGF-β2 and FGF-2, PBS 
or Decorin solution, ready for injection. Intravitreal Injections with the loaded micropipettes were 
done at the angle shown in Figure 4 at the temporal side of the eye and, to relieve ocular pressure, 
the eye was penetrated trans-sclerally with a 23G needle tip at a point 180° from the original 
injection site (nasally), which also created a retinal injury. For retinal detachment in animal group 1, 
5 - 10µl of 0.25% Healon (Abbot Medical Optics, Santa Ana, California, USA) in PBS was injected into 
the subretinal space. 
 
 
 
Figure 4: A diagram of the rat eye is shown. The 
vitreous body is found just posterior to the lens and 
lies adjacent to the retina. The injection site and 
angle of injection is also shown. Injections were 
done temporally. Since the vitreous is a closed 
cavity, injection of substances will elevate the 
pressure. To avoid pressure induced damaged to 
retinal ganglion cells, the vitreous was penetrated 
trans-sclerally with a needle tip at a point 180° to 
the original injection site (nasally). 
 15 | P a g e  
 
2.5 Tissue preparation – immunofluorescence 
At the end of the study (day 28), animals from groups 2 and 3 were intraperitoneally injected with 
0.5ml Ketamine + Medetomidine. After 15 minutes, 4% paraformaldehyde (PFA; TAAB, Reading, UK) 
in PBS was used for intracardiac perfusion with concurrent clamping of the descending aorta to limit 
fixation to the head region. Eyes were dissected out by cutting around the orbit and separating the 
eye from the extraocular muscles and optic nerve. The cornea and lens of the eyes were dissected 
away leaving a retinal cup which was imaged on a dissecting microscope, before being post-fixed in 
4% PFA in PBS for 24 hours at 4°C. The tissue was then cryoprotected in 10%, 20% and 30% sucrose 
solution in PBS for 24 hours, each at 4°C. Eyes were then embedded using optimal cutting 
temperature (OCT) embedding medium (Thermo Shandon, Runcorn, UK) in peel-away mould 
containers (Agar Scientific, Stansted, Essex, UK) which were kept under crushed dry ice for 5-10 
minutes to allow the OCT to freeze. Frozen tissue blocks were stored at -20°C to be sectioned. 
Following embedding, eyes were sectioned on a cryostat microtome (Bright, Huntingdon, UK) 
maintained at -22°C and at a thickness of 15µm before being mounted on positively charged glass 
slides (Superfrost Plus, Fisher Scientific, Pittsburgh, USA). Slides were left to dry overnight at 37°C 
before being stored at -20°C. 
2.6 Tissue preparation – Western blot 
At the end of the study (day 28), animals from groups 1 and 4 plus intact animals were sacrificed by 
intraperitoneal injection of Euthanal (sodium pentobarbital). The eyes were removed and retinae 
dissected out and snap frozen in liquid nitrogen. The tissue was defrosted on ice, and homogenized 
for 1 minute in cold lysis buffer (150mM NaCl, 20mM Tris HCl (Fisher BioReagents, UK), 1mM EDTA 
(Fisher BioReagents), 0.5mM EGTA, 1% NP-40 and 5µl/ml protease inhibitor cocktail). The 
homogenized tissue was left on ice for 20 minutes before being centrifuged at 16,000 xg for 30 
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minutes at 4°C. The supernatant was collected and the protein concentration determined using the 
colorimetric DC protein assay (BioRad, Hercules, CA, USA) as per the manufacturer’s instructions. 
2.7 Western blot 
Samples (40µg total protein) were made up to 20ml in 2x Laemmli loading buffer and incubated for 4 
minutes at 90°C. Samples were loaded and separated on an 8% SDS-polyacrylamide gel (Life 
Technologies, Invitrogen, UK) while in running buffer (192mM glycine, 25mM Tris base, 0.1% SDS 
(Fisher BioReagents)) for 2 hours. PVDF membranes (Millipore, Gloucestershire, UK) were activated 
in methanol for 1 minute and then washed in transfer buffer (192mM glycine, 25mM Tris base, 20% 
methanol, 0.01% SDS). Proteins were transferred to the PVDF membranes in transfer buffer before 
being washed in TTBS (11.6mM Tris base, 38.1mM Tris HCl, 150mM NaCl, 0.05% Tween 20; pH 7.4). 
PVDF membranes were blocked for 1 hour in blocking solution (TTBS, 5% non-fat milk) and then 
incubated with the relevant primary antibody diluted in blocking solution for 2 hours at room 
temperature. Membranes were then washed for 3 X 10 minutes in TTBS before incubation with a 
HRP-conjugated secondary antibody for 1 hour at room temperature. Membranes were developed 
using an enhanced chemiluminescence system (Amersham, Buckinghamshire, UK). Blots were 
stripped using 2 X 10 minutes of stripping buffer (200mM glycine, 3.5mM SDS and 1% Tween 20), 2 X 
10 minutes of PBS and 2 X 5 minutes TTBS before being reprobed with other relevant antibodies 
from thereafter. 
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2.8 Antibodies 
Antigen 
specificity 
Animal 
raised in 
Dilution 
(immunofluorescence) 
Dilution 
(Western blot) 
Supplier 
Laminin Rabbit 1:200 1:250 Sigma 
Fibronectin Rabbit N/A 1:500 Sigma 
GFAP Rabbit 1:250 N/A Sigma 
α-SMA Mouse 1:100 1:1000 Sigma 
β-actin Mouse N/A 1:1000 Sigma 
ED1 (CD68) Mouse 1:200 N/A Serotec 
Collagen IV Rabbit 1:200 N/A Abcam 
Alexa-488 
Mouse IgG 
Goat 1:400 N/A Molecular 
Probes 
Alexa-594 
Rabbit IgG 
Goat 1:400 N/A Molecular 
Probes 
HRP-Mouse 
IgG 
Sheep N/A 1:1000 GE 
Healthcare 
HRP-Rabbit 
IgG 
Donkey N/A 1:1000 GE 
Healthcare 
Table 2: A list of antibodies used, animals they were raised in, dilution used for each technique (if applicable) and the 
supplier. 
2.9 Immunohistochemistry 
Frozen Sections were allowed to equilibrate to room temperature for 30 minutes before being 
hydrated in PBS for 2 X 5 minutes. Tissue was then permeabilized in 0.1% triton x-100 in PBS for 20 
minutes at room temperature. Tissue was washed for 2 X 5 minutes in PBS and isolated with a 
hydrophobic PAP pen (Immedge pen; Vector Laboratories, Peterborough, UK). The tissue was 
blocked (75µl; 0.5% bovine serum albumin (g/ml), 0.3% Tween-20, 15% normal goat serum (Vector 
Laboratories) in PBS) in a humidified chamber for 30 minutes at room temperature. After the 30 
minutes block, tissue was incubated with primary antibody diluted in antibody diluting buffer (ADB; 
0.5% bovine serum albumin (g/ml), 0.3% Tween-20 in PBS) overnight at 4°C. The following day slides 
were left to equilibrate with room temperature for 20 minutes before being washed in 3 X 5 minutes 
of PBS. Tissue sections were then incubated with secondary antibody diluted in ADB for 1 hour in a 
hydrated incubation chamber at room temperature. After the 1 hour, slides were washed in 3 X 5 
minutes of PBS, mounted in Vectorshield mounting medium containing DAPI (Vector Laboratories) 
and stored at 4°C prior to microscopic analysis. 
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2.10 Microscopy and analysis 
Sections were analysed blind using a Zeiss Axioplan-2 fluorescent microscope (Carl Zeiss Ltd, 
Hertfordshire, UK) with images taken at 20X magnification using Axiocam HRc camera and Axiovision 
software (Carl Zeiss Ltd). Four sections per animal were used and 4 animals per treatment group 
with all sections used being in the same plane by ensuring the optic nerve was visible. 
For Western blots, developed membranes were scanned onto computer and densitometry was 
performed on each band in the image using Photoshop CS3 (Adobe Systems inc, San Jose, CA, USA). 
This was done using a specific sized boxed drawn around the band and mean pixel intensity 
calculated and standardized to β-actin controls. Laminin bands were contrast enhanced on 
Photoshop CS3 to improve visibility. 
2.11 Statistics 
Densitometric data was standardised to β-actin controls first and then secondly to intact controls 
and thus given as normalised values.  
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3 Results 
3.1 Overview 
The study aimed to induce PVR in a rat and explore Decorin as a potential treatment option in 
ameliorating the fibrosis associated with the disease. A second aim of the study was to explore 
methods of quantifying retinal/vitreal fibrosis to determine the best technique. Group 1 was injected 
subretinally with Healon and then intravitreally with either PBS (left eye) or TGF-β2/FGF-2 (right eye). 
Group 2 was injected intravitreally with either PBS (left eye) or TGF-β2/FGF-2 (right eye). Group 3 
was injected intravitreally with TGF-β2/FGF-2 with delayed (day 14) intravitreal injection of either 
PBS (left eye) or Decorin (right eye). Group 4 was injected intravitreally with TGF-β2/FGF-2 with 
intravitreal injection of either PBS (left eye) or Decorin (right eye). Groups 1 and 4 were analyzed 
using Western blot whereas groups 2 and 3 were analysed using immunohistochemistry. 
3.2 Group 1 
Subretinal injection of Healon increased fibronectin density in the retina at day 28 by over 2-fold 
(Figure 5A) and the laminin by more than 3-fold (Figure 5B). Injection of TGF-β2/FGF-2 did not have 
any further effect on laminin/fibronectin density compared to PBS. Subretinal Healon injection with 
intravitreal TGF-β2/FGF-2 increased α-SMA by 3-fold (Figure 5C) whereas without TGF-β2/FGF-2, no 
effect compared to control was seen.  
 20 | P a g e  
 
 
Figure 5: Western blots for animal group 1 that received a subretinal injection of Healon and intravitreal injection of either 
transforming growth factor-β2/fibroblast growth factor-2 (TGF-β2/FGF-2; right eye) or phosphate-buffered saline (PBS; left 
eye). Blots are shown above with densitometric data for fibronectin (A), laminin (B) and α-smooth muscle actin (α-SMA; C) 
displayed. Data is given as arbitrary values standardised to β-actin loading controls and then to intact eyes. Each treatment 
group consisted of 4 animals with samples pooled together before blotting. 
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3.3 Group 2 
Gross macroscopic images of retinae from eyes intravitreally injected with PBS (left, Figure 6A) or 
TGF-β2/FGF-2 (right, Figure 6B) yielded no signs of fibrosis and no discernible morphological 
difference at day 28. Small zones of haemorrhage (white arrows) could be visualised in both 
treatment groups. Immunohistochemically stained retinal sections showed GFAP (Figure 7A and B), 
laminin (Figure 7D and E) and collagen IV (Figure 7F and G) positive regions in the ganglion cell layer 
whereas ED1 (Figure 7A and B) and α-SMA (Figure 7D and E) was absent. No observable differences 
could be seen between treatment groups. 
 
 
Figure 6: Gross macroscopic images of eyes from group 2 animals injected with either phosphate-buffered saline (PBS; left, 
A) or transforming growth factor-β2/fibroblast growth factor-2 (TGF-β2/FGF-2; right, B). White arrows point to areas of 
haemorrhage. Images were taken after removal of cornea and lens with multiple images at different exposures taken and 
merged into a high dynamic range image on Photoshop CS3. All images are representative of the 4 animals used. Scale bars 
= 1mm. 
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Figure 7: Immunohistochemically 
stained 15µm thick sections of the retina 
from group 2 animals are shown (A-G). 
Retinae are from eyes injected with 
either phosphate-buffered saline (PBS; 
A, D and F) or transforming growth 
factor-β2/fibroblast growth factor-2 
(TGF-β2/FGF-2; B, E and G). Sections 
were stained for ED1 and glial fibriliary 
acidic protein (GFAP; A and B), α-smooth 
muscle actin (α-SMA) and laminin (D and 
E) and collagen IV (F and G). A negative 
control whereby the primary antibody 
was omitted is also shown (C) with the 
outer nuclear layer (ONL), inner nuclear 
layer (INL) and ganglion cell layer (GCL) 
labelled. In all instances, DAPI was used 
as a counter-stain. All images are 
representative of the 4 animals used per 
treatment group. Scale bars = 50µm. 
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3.4 Group 3 
Gross macroscopic images of retinae from eyes intravitreally injected with TGF-β2/FGF-2 and either 
PBS (left, Figure 8A) or Decorin (right, Figure 8B) yielded no signs of fibrosis and no discernible 
morphological difference at day 28. Immunohistochemically stained retinal sections showed GFAP 
(Figure 9A and B), laminin (Figure 9D and E) and collagen IV (Figure 9F and G) positive regions in the 
ganglion cell layer whereas ED1 (Figure 9A and B) and α-SMA (Figure 9D and E) was absent. No 
observable differences could be seen between treatment groups. 
 
 
 
Figure 8: Gross macroscopic images of eyes from group 3 animals injected with transforming growth factor-β2/fibroblast 
growth factor-2 (TGF-β2/FGF-2) and treated at day 14 with either phosphate-buffered saline (PBS; left, A) or Decorin (right, 
B). Images were taken after removal of cornea and lens with multiple images at different exposures taken and merged into 
a high dynamic range image on Photoshop CS3. All images are representative of the 4 animals used. Scale bars = 1mm 
 24 | P a g e  
 
Figure 9: Immunohistochemically 
stained 15µm thick sections of the 
retina from group 3 animals are shown 
(A-G). Retinae are from eyes injected 
with transforming growth factor-
β2/fibroblast growth factor-2 (TGF-
β2/FGF-2) and treated at day 14 with 
either phosphate-buffered saline (PBS; 
A, D and F) or Decorin (B, E and G). 
Sections were stained for ED1 and glial 
fibriliary acidic protein (GFAP; A and B), 
α-smooth muscle actin (α-SMA) and 
laminin (D and E) and collagen IV (F and 
G). A negative control whereby the 
primary antibody was omitted is also 
shown (C) with the outer nuclear layer 
(ONL), inner nuclear layer (INL) and 
ganglion cell layer (GCL) labelled. In all 
instances, DAPI was used as a counter-
stain. All images are representative of 
the 4 animals used per treatment 
group. Scale bars = 50µm. 
 
 
3.5 Group 4 
Intravitreal injection of TGF-β2/FGF-2 (and PBS) increased fibronectin levels in the retina by over 2-
fold (Figure 10A) and laminin levels by almost 5-fold (Figure 10B) compared to intact. Injection of 
Decorin alongside TGF-β2/FGF-2 further increased fibronectin density, yielding a 3-fold elevation 
above intact. Laminin density, however, was reduced by half in the Decorin treated group. 
Intravitreal TGF-β2/FGF-2 elicited a minor increase in α-SMA density (Figure 10C) that was seen with 
or without the presence of Decorin.  
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Figure 10: Western blots for animal group 4 that received intravitreal injection of transforming growth factor-β2/fibroblast 
growth factor-2 (TGF-β2/FGF-2) with either intravitreal Decorin treatment (right eye) or intravitreal phosphate-buffered 
saline (PBS) treatment (left eye). Blots are shown above with densitometric data for fibronectin (A), laminin (B) and α-
smooth muscle actin (α-SMA; C) displayed. Data is given as arbitrary values standardised to β-actin loading controls and 
then to intact eyes. Each treatment group consisted of 4 animals with samples pooled together before blotting. 
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4 Discussion 
4.1 Overview 
For quantifying retinal fibrosis, Western blot proved the superior method whereas for 
immunohistochemistry, identifying areas of fibrosis proved impractical without a defined region of 
fibrosis to analyse. Western blots performed on animal group 1 showed that a subretinal injection of 
Healon was able to induce retinal fibrosis, which was evident by the increased fibronectin and 
laminin density; however no rise in α-SMA was seen. TGF-β2/FGF-2 intravitreal injection induced no 
additional fibrosis to Healon injected eyes but did induce a 3-fold increase in α-SMA, indicating an 
increase in RPE cell differentiation (EMT) into α-SMA+ myofibroblasts. Without a subretinal injection 
of Healon (group 4), intravitreal injections of TGF-β2/FGF-2 induced increases in retinal fibronectin 
and laminin. Bi-weekly injections of Decorin reduced retinal laminin density in this group but 
increased fibronectin density. No substantial change in α-SMA was seen after intravitreal TGF-
β2/FGF-2 injection, with or without Decorin in this animal group. 
4.2 Group 2 and 3 
Group 2, which was intravitreally injected with TGF-β2/FGF-2 in the right eye and PBS in the left eye 
and group 3, which was the same as group 2 but with bi-weekly Decorin injections beginning at day 
14, was analysed immunohistochemically. This proved an impractical method to identify and 
quantify retinal fibrosis. Gross images of the fundus (Figure 6 and 8) were taken before sectioning 
and with no observable retinal detachment or fibrosis seen; it seems that only a mild PVR was 
induced by the growth factor treatments. Immunohistochemical staining (Figure 7 and 9) showed 
the presence of a laminin+ basement membrane in the retina and GFAP+ glia in the ganglion cell layer 
while also showing an absence of ED1+ macrophages and α-SMA+ myofibroblasts. Few conclusions 
can be drawn from the immunohistochemical analysis of these two groups other than an apparent 
lack of visible inflammation and EMT, which are hallmarks of PVR (Pastor et al., 2002). 
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4.3 Group 1 
Subretinal injection is not a common model of PVR since it induces retinal detachment rather than 
PVR, despite retinal detachment (even if surgically corrected) being the most common cause of PVR 
in patients (Pastor, 1998). Where subretinal injection is used as an experimental model, historically, 
it was to transfect RPE cells to cause expression of a desired growth factor and not to simply detach 
the retina (Agrawal et al., 2007). In the present study, however, subretinal injection and the resulting 
retinal detachment increased the fibronectin and laminin density within the retinal tissue (detected 
by Western blot; Figure 5), an observation seen in PVR patients (Hiscott et al., 1999). The addition of 
TGF-β2/FGF-2 did not increase the response so it can be concluded that the retinal fibrosis after 
retinal detachment, particularly laminin and fibronectin, was not enhanced by exogenous TGF-
β2/FGF-2. This may be due to the retinal detachment itself inducing the release of endogenous TGF-
β2/FGF-2, though without running an assay for these cytokine/growth factors on vitreous from these 
animals, this is speculative. 
Our results demonstrated a substantial increase (3-fold) in α-SMA after intravitreal TGF-β2/FGF-2 
injection compared to intact eyes or those receiving subretinal injection alone. This is not surprising 
since a previous paper has shown vitreal samples from PVR patients, which have elevated levels of 
TGF-β, induce contraction of collagen gels and induce a 2.5-fold increase in α-SMA in hyalocytes 
isolated from the eye (Kita et al., 2008). The increase in α-SMA witnessed in this study was inhibited 
when antibodies to TGF-β were added but not when fasudil, an inhibitor of the RhoA pathway was 
used, suggesting the Smad pathway is responsible. Since FGF-2 increases the proliferation of RPE 
cells and myofibroblasts, it is may also be responsible for the increase in α-SMA/myofibroblasts 
(Pastor, 1998). 
As mentioned previously, α-SMA+ myofibroblasts derive from RPE cells by a special type of 
differentiation known as EMT. A previous paper has shown RPE cells undergo EMT in response to 
TGF-β both in vitro and in vivo (Saika et al., 2004). The authors attributed this to the Smad pathway 
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by firstly showing TGF-β activated the Smad pathway within 30 minutes of administration and 
secondly, using Smad3-knockout mice to completely prevent both the EMT and the enhanced α-SMA 
expression. In a similar study the authors inhibited EMT by over expressing Smad7, an inhibitor in 
the Smad pathway (Saika et al., 2007). 
Since α-SMA+ myofibroblasts are so important in PVR by transforming a regular retinal detachment 
into a tractional retinal detachment (Pastor et al., 2002) it can be said that injecting TGF-β2/FGF-2  
intravitreally alongside the subretinal Healon injection is the better model of PVR in comparison to 
the subretinal injection alone. This leaves the question as to how a retinal detachment in patients 
induces EMT and if it is through inducing the release of endogenous TGF-β, why has it not done so in 
this particular model. 
4.4 Group 4 
The observation that intravitreal TGF-β2/FGF-2 induced retinal fibrosis, assessed by Western blot 
(Figure 10), corroborates what is previously known, that PVR patients have increased concentrations 
of TGF-β2 in the vitreous (Connor et al., 1989) and suggests that this correlation is causative. 
Although Decorin, an anti-fibrotic agent was able to reduce laminin density by 2-fold, paradoxically, 
Decorin further increased fibronectin density over the initial increase induced by TGF-β2/FGF-2. This 
is in direct conflict with previous work that shows Decorin reduces TGF-β-induced fibronectin 
production in the cornea (Mohan et al., 2010). 
Interestingly, intravitreal TGF-β2/FGF-2 injection did not increase α-SMA expression like it did in 
group 1, suggesting that retinal detachment is a required factor in TGF-β2-induced EMT. Since the 
two previous papers (Saika et al., 2004; Saika et al., 2007) showing TGF-β2-induced EMT also used 
retinal detachment as their model, it is likely that retinal detachment is required, possibly to allow 
TGF-β2 to act on the RPE cells situated underneath the retina. However, one study refutes this 
contention by showing that, although vitreal TGF-β2 correlates with PVR in patients, high levels of 
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TGF-β2 in the subretinal fluid protect against PVR (Dieudonne et al., 2004). This paper would argue 
that whatever TGF-β is interacting with to induce or augment PVR, its interactions cannot be with 
RPE cells since they are in direct contact with the subretinal fluid. 
Due to lack of elevated α-SMA, we were unable to test Decorin’s efficacy at reducing any α-SMA 
overexpression, which is an effect we would have expected. This expectation is based on previous 
research in the cornea whereby TGF-β-induced EMT was prevented by transfecting corneal 
fibroblasts to express Decorin (Mohan et al., 2010). 
4.5 Future work 
Unfortunately, due to technical issues and limited time, a non-denatured Western blot was not 
performed adequately and as such, this remains an important future experiment to determine 
further the extent of fibrosis in this model. Previous papers have shown that RPE cells produce 
collagen I in response to TGF-β in a Smad dependant fashion (Saika et al., 2007) and so, similar to 
what is seen with laminin, collagen would be expected to increase in the TGF-β2/FGF-2 treated 
groups and to be attenuated in the groups receiving Decorin. Repeats of standard, denatured 
Western blots will also need to be done to obtain enough data to perform statistical tests. This may 
also remove some of the paradoxical results seen, such as Decorin increasing fibronectin density. 
More markers of fibrosis and epiretinal membrane formation are available and analysis of these and 
how they change in this model is an important future experiment. One example is GFAP since, as 
mentioned previously, GFAP+ glial cells are an important contributor to wound healing in the CNS 
and retina and make up a significant part of the cellular component of epiretinal membranes (Pastor 
et al., 2002). A recent study used TGF-β antibodies to inhibit PVR in a mouse model and significantly 
reduce fibrosis, while interestingly, only using GFAP as a marker for subretinal fibrosis (Zhang and 
Liu, 2012). Other markers involved in fibrosis and remodelling are matrix metalloproteinases (MMP) 
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of which, MMP-2 and MMP-9 were found at significantly high levels in PVR patients that were 
correlated with the development of postoperative PVR (Kon et al., 1998).  
Since subretinal Healon and intravitreal TGF-β2/FGF-2 injection worked best at inducing measurable 
retinal fibrosis, evident by the increase in fibrotic markers (fibronectin and laminin) and markers of 
EMT (α-SMA) by Western blot, the next stage would be to assess Decorin as a suitable treatment in 
this particular model. One such paper has already done preliminary work in assessing Decorin as a 
treatment option for PVR (Nassar et al., 2011). Using a retinal injury-induced animal model of PVR, 
they showed a smaller fibrosed area and a reduction in grade of PVR on a clinical grading scale 
(performed by an Ophthalmologist). As well as corroborating our findings of decreased fibrosis they 
also performed an examination for any drug related toxicity and found none, thus suggesting 
Decorin to be a safe future drug. Unfortunately, they failed to look for key fibrotic proteins and 
assess their protein expression, as was done in this study, and thus key conclusions such as the 
extent of EMT and changes in individual protein levels are not possible. 
In this present study we have assumed that subretinal injection of Healon led to retinal detachment, 
however, this assumption was never verified. With in vivo imaging techniques, such as a scanning 
laser ophthalmoscope and an optical coherence tomography machine, it would be possible to view 
retinal detachment in vivo (Cebulla et al., 2010) and accurately quantify it. This is more reliable than 
trying to visualize retinal detachment after the animal is sacrificed since the process of tissue 
preparation gives rise to artefacts. 
An important consideration is how translational Decorin is as a treatment. If found to have efficacy 
in treating PVR then, along with its good safety profile, an effective form of intravitreal delivery will 
need to be established that will avoid repeated intravitreal injections. One such study used a long 
term delivery method with microspheres containing the anti-proliferative agent retinoic acid in a 
rabbit model of PVR (Giordano et al., 1993). They showed that following a single injection of the 
microspheres, drug release remained constant for 30 days and thus bypassing the need for repeated 
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intravitreal injections. A similar method allowing the sustained release of Decorin would overcome 
the impractical bi-weekly intravitreal injections and is necessary for clinical trials. 
Finally, an important consideration is the time frame of the study, and how long animals need to be 
left following retinal detachment and/or TGF-β2/FGF-2 injection before a mature scar forms. In the 
present study animals were left for 28 days however, areas of haemorrhage were seen in the eyes, 
suggesting fibrosis was still in its early stages and thus, a longer time frame is needed before a scar 
and possibly epiretinal membranes form. 
4.6 Conclusion 
Two important conclusions can be drawn from this study. The first is that immunohistochemistry is a 
substandard method for quantifying fibrosis, particularly in PVR where no isolated region can be 
analysed. Future experiments should concentrate on Western blots and possibly PCR to reliably 
quantify changes in retinal fibrosis related proteins. 
The second conclusion is that subretinal injection of Healon induces retinal fibrosis, and when 
coupled with TGF-β2/FGF-2, also induces EMT and the formation of myofibroblasts. Based on our 
limited assessment of markers for fibrosis and PVR, this proved to be the best model of PVR for 
future use. Decorin, although showing promise in being able to reduce laminin density by a half, 
remains untested in our preferred model. Future work concentrating on one particular model, 
Decorin’s effects on this model and a larger array of PVR related protein changes analysed by 
Western blot will, (1), shed light on the pathogenesis of PVR in our model and, (2), provide stronger 
evidence of Decorin’s potential as a treatment for PVR. 
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